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Lysophosphatidylcholine Acyltransferases (LPCATs) are Lipid modifying enzymes that sig-
nificantly regulate changes in the glycerophospholipid components of the macrophage membrane
phospholipid bilayer. LPCAT2 is a subtype of LPCAT that regulates inflammatory responses
to infection by lipopolysaccharides and lipopeptides. LPCAT2 co-localises with TLR4 and pre-
vents its translocation to the signalling site (lipid rafts) of macrophage membranes. The first
response to inflammation involves infiltration of macrophages to the infected site, where they
fight infection by phagocytosing the microbial pathogen. Changes in the macrophage membrane
phospholipid bilayer are essential for phagocytosis and receptor signalling. Regulation of protein
acylation is also an integral mechanism for macrophage function. LPCAT2 influences acylation
of proteins such as RNF19B – An E3 Ubiquitin Ligase. This research aims to understand further
the molecular mechanisms of the enzyme – LPCAT2, that leads to its involvement in regulating
macrophage inflammatory responses.
Building on pre-existing work on the role of LPCAT2 in inflammation, the primary research
question is – “How Does LPCAT2 regulate the expression and function of receptors that mediate
macrophage inflammatory responses?”
Comparison of the expression of proteins and genes in RAW264.7 cells with or without
LPCAT2 silenced determined the possible mechanisms by which LPCAT2 regulates inflammation
in macrophages. This study analysed the expression of TLR4 and its co-receptors (CD14 and
MD2) – which play a significant role in macrophage inflammatory responses to infection by
gram-negative bacteria. The expression of inflammatory cytokines such as IL6, TNFU, IP10,
and IFNV, which are synthesised following activation of TLR4, was also studied. Furthermore,
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the influence of LPCAT2 in the expression and function of acylated proteins such as RNF19B
was studied. Analysis of the regulation of lysine acetylation by LPCAT2 helps to understand
the role of LPCAT2 in protein acylation.
The results show that LPCAT2 regulates the expression of CD14 and RNF19B. It also
influences the expression of lysine-acetylated proteins. Finally, LPCAT2 and RNF19B could
modulate macrophage inflammatory responses to both bacterial and viral infection.
This study shows that LPCAT2 modulates macrophage inflammatory responses by influenc-
ing CD14 and RNF19B expression. It also suggests a novel basis for further studies on the role
of LPCAT2 in lysine acetylation of proteins during macrophage inflammatory responses.
This thesis contributes novel knowledge to the fields of molecular immunology and biochem-
istry. The future establishment of the role of LPCAT2 in regulating inflammation can lead to
its discovery as a biomarker or a drug-target for various immunological diseases.
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Inflammation is a normal physiological response that protects and repairs tissues from in-
jury. The intensity of inflammation is relative to the degree of tissue injury; therefore, excessive 
tissue injury would cause extreme inflammatory responses in a tissue [2]. However, a healthy 
inflammatory response is well regulated and is characterised by the following pathological fea-
tures: vasodilation of blood vessels, enhanced permeability of the capillaries, clotting, migration 
of large numbers of granulocytes and monocytes, and tissue swelling.
1 Inflammatory Disorders
Excessive release of pro-inflammatory cytokine is a crucial feature of a dysregulated inflammatory 
response by the innate immune system [3,4]. Dysregulated inflammation is central to several life-
threatening syndromes; including macrophage activation syndrome, influenza, and sepsis [2–12].
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1.1 Sepsis
One of the common examples of hyper-inflammatory diseases in the UK is sepsis. Sepsis is
a life-threatening organ dysfunction caused by a dysregulated host response to infection from
pathogens such as gram-negative or gram-positive bacteria [13]. Sepsis could lead to pathological
symptoms such as hyperthermia or hypothermia, organ dysfunction, and could eventually lead
to death [14]. Sepsis is the cause of 44,000 deaths annually in the UK, and 250,000 deaths
yearly in the USA [15,16]. There are several biomarkers for diagnosis, prognosis, and treatment of
sepsis [17,18]. However, due to gaps in understanding of the immune system, effective therapy for
sepsis is yet to be found [19]. Therefore, it is essential to understand the molecular mechanisms
of hyper-inflammation to manage or treat syndromes like sepsis.
1.2 Macrophage Activation Syndrome
Macrophage activation syndrome is an inflammatory disorder that often occurs in rheumatic
disorders, hemophagocytic lymphohistiocytosis, and the recent COVID19 [20,21]. Proliferation
and activation of T cells and macrophages and excessive release of pro-inflammatory cytokines
by macrophages known as a cytokine storm are features of macrophage activation syndrome.
There is no clearly defined pathological mechanism of macrophage activation syndrome; however,
IL6, TNFU, and interferons are significant mediators of this syndrome. Hemophagocytosis, which
defines the destruction of blood cells (such as leukocytes, erythrocytes, blood platelets and their
precursors) in tissues (especially in the bone marrow) by phagocytic histiocytes [22], – is also a
pathological feature of macrophage activation syndrome [9,23–26].
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1.3 Influenza
Influenza is another common disease that has hyper-inflammation as a pathological feature. Sev-
eral strains of influenza viruses such as the Influenza A/H3N2, influenza A/H1N1, and influenza
B are associated with significant outbreaks around the world, resulting in ≥500,000 deaths [27,28].
Hyper-inflammation caused by excessive release of inflammatory mediators is not only a
pathological feature of infectious diseases. However, it is also present in non-infectious diseases
such as respiratory disorders, multiple sclerosis, lymphoma and leukaemia [29].
2 In Vitro Models for Studying Inflammation
In Vitro models of inflammation refer to a wide variety of tools used for studying and under-
standing the effects of inflammation outside of a whole living organism. In recent years, In Silico
analysis has contributed mostly to in vitro studies [30]. It is often based on already established
knowledge and used to predict unknown phenomena [31]. For instance, it can predict the prob-
ability of protein-protein interaction or post-translational modification based on recognition of
established motifs or binding sites of enzymes [32–34].
Despite the usefulness of computational tools, experiments using cell models are essential. When
choosing a cell model, it is essential that the pathway or mechanism of interest is expressed in
the cell and can be quantified [35]. Most of the cell models used for studying inflammation have
receptors that would recognise ligands and can secrete cytokines which are then quantified and
analysed [36]. The diverse functions of macrophages are studied using various secondary and
primary macrophage cell lines. The key difference between primary and secondary cell lines is
that primary cells are obtained directly from an organism or a tissue.
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In contrast, secondary cell lines are often genetically manipulated to enable them to live and
function longer than primary cells (immortalisation). Some examples of secondary cell lines
include RAW264.7, Mono-Mac 6, and MPI macrophage-like cells [37–39], and Bone-Marrow De-
rived Macrophages (BMDM) are primary macrophages in experimental studies. Primary cells
are more trustworthy than secondary cell lines because they are more similar or comparable
to In Vivo models, and can sometimes respond differently to secondary cell lines in the same
experimental conditions. For instance, J774 macrophage-like cells and BMDM challenged with
M. tuberculosis showed a differential intensity of response [40].
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Chapter 2
Innate Recognition of Microbial Pathogens
1 An Overview of Innate Immunity
Innate immunity is the immediate response of the immune system to cell invasion by microbial
pathogens. It limits the damage that can be caused by exposure to micro-organisms and inte-
grates signals to induce the adaptive immune system. The first line of defence consists of physical
and chemical barriers. The physical barriers refer to the epithelial skin layer and mucosal and
glandular surfaces that block the passage of pathogens into the body. The biochemical barri-
ers refer to complement proteins and other antimicrobial proteins that destroy pathogens [41–45].
When the first line of defence fails to prevent the passage of pathogens into the body, cells of
the innate immune system such as; macrophages, neutrophils, dendritic cells, and monocytes
recognise PAMP through PRR and are activated [46]. Cellular Innate immune responses mainly
involve phagocytosis of the PAMP and release of inflammatory cytokines and chemokines that
lead to inflammation [47]. Phagocytosis of microbes leads to the formation of phagolysosomes- a
fusion of phagosomes and lysosomes. Phagolysosomes destroy microbes because of the presence
19
of antimicrobial proteins, low pH, hydrolytic enzymes, ROS, and RNS.
Previously, only cells of the adaptive immune system were thought to have memory. However,
in recent years a phenomenon known as trained innate immunity has been described. Trained
immunity refers to the ability of innate immune cells to possess a memory of infection [48]. In
trained immunity, there is an enhanced response to microbial contagion [49]. Moreover, several
researchers have suggested regulation of trained immunity by epigenetic reprogramming. For
instance, mono-methylated histone (H3K4Me1 – which mainly binds DNA and activates or
represses genes) regulates trained immunity [50]. Even so, some scientists have postulated that
trained immunity is responsible for the non-specific protective effects of certain vaccines [51]. The
discovery of trained innate immunity, which is controlled by epigenetic reprogramming, shows
that there is a lot more to understand about the regulation of the innate immune system.
2 Macrophages
Macrophages are the principal effector cells of the innate immune system [44]. The primary func-
tions of macrophages include; elimination of dead or damaged cells, foreign micro-organisms,
and metabolic waste. They also secrete a wide range of bioactive molecules such as IL6, IP10,
TNFU, and growth factors that contribute to inflammation. Tissue-resident macrophages may
also carry out extra functions depending on the need of the resident tissue. For instance, alveolar
macrophages clear up surfactants in the lungs [52,53]. Various environmental stimuli regulate the
basal functions and responses to danger signals by macrophages. They are present in multiple
tissues and maintain homeostasis by co-ordinating developmental, metabolic, and immunologi-
cal functions. Some metabolic stimuli that regulate macrophage function include; haem which
stimulates the formation of red-pulp macrophages, retinoic acid which promotes the generation
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of peritoneal macrophages, and fatty acids contribute to the activation of macrophages in obe-
sity. On the other hand, danger signals include components of microbial organisms such as
LPS, lipopeptides, and nucleic acids. Moreover, extracellular ATP, alarmins, and HMGB1 are
examples of endogenous danger signals [54]. Some researchers have reported that macrophages
show phenotypic characteristics based on the environmental stimulus. However, phenotypic
mechanisms are not fully understood. The M1 phenotype is commonly known as the activated
macrophage which promotes inflammatory responses along with T1 cell effector responses. LPS
and IFNW are conventional stimulators of the M1 macrophage phenotype. In contrast, the M2
macrophage phenotype has a reduced ability to induce pro-inflammatory cytokines and exhibits
a preference for metabolising arginine and phagocytic activities. The commonly used stimu-
lators for M2 macrophage phenotype are IL4 and IL13. There are suggestions that epigenetic
reprogramming of macrophages contributes to the switch to M1 and M2 macrophage pheno-
types. However, there are still gaps in the understanding of the mechanisms involved in M1 and
M2 macrophage phenotypes [55]. Macrophages can differentiate from yolk sac erythro-myeloid
progenitors or hematopoietic progenitors. Poor differentiation of resident macrophages of the
brain (microglia) during foetal development can cause neuropsychiatric disorders [52,55].
Table 1: Comparison of Macrophage Subtypes
Parameter M1(Clasically Activated) M2(Alternative Activated)
Inducers GMCSF, IFNW, LPS IL4, MCSF, IL10
Upregulated Cytokines Pro-inflammatory cy-




Downregulated Cytokines IL10, Arginine-1 TNFU, IL6, iNOS
Markers CD16, CD32, CD64, CD86 CD206
Inducer refers to molecules that can induce the polarization of macrophages into M1 or M2
phenotypes. Markers are molecules that are used experimentally to identify the various
phenotypes of macrophages because of their significantly high expression in the respective
phenotype of macrophages [56–60].
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3 Macrophage Pathogen-Recognition Receptors
Some of the known pathogen-recognition receptors include Nod-Like receptors, RIG-I-Like re-
ceptors, C-Type Lectin receptors, and Toll-Like receptors. Nod-Like and RIG-I-Like receptors
are cytoplasmic. RIG-I-like receptors are RIG-I, MDA5, and LGP2 helicases which recognise
both single-stranded and double-stranded viral RNA in the cytosol. They induce high levels
of type I interferons to fight viral infection [61,62]. On the other hand, Nod-Like receptors have
22 subtypes classed into four functional categories which include; inflammasome assembly, sig-
nalling transduction, transcription activation, and autophagy. Unlike RIG-I-Like receptors, they
recognise a variety of pathogens, including flagellin, viral RNA, and peptidoglycan. Activation
of Nod-Like receptors can result in the induction of IL1V through the inflammasome pathway,
and the activation of transcription factors, NF^B and CREBBP [63–66].
C-type lectin receptors are commonly found on monocytes, macrophages, and dendritic cells.
They recognise mannans and peptidoglycans from microbes and mainly promote phagocyto-
sis [67–70].
TLRs are activated by components of microbial pathogens and transduce signals through
TIR-containing adapter proteins such as MyD88, Mal, TRIF, and TRAM. The adapter proteins
interact with other proteins such as TRAF3/6, IRAK1/4/2, and IKK proteins. IKK proteins
then interact with transcription factors IRF3 and NF^B leading to the activation of these tran-
scription factors, and hence the production of inflammatory cytokines such as TNFU, IL1V, IL18,
IL10, and type I interferons [71–76]. TLRs are characterised by the presence of LRR motifs and
TIR domains; TIR-binding adapter proteins bind to the TIR domains. TLR1/2 heterodimer
binds to triacyl lipopeptide, whereas TLR2/6 heterodimer recognises diacyl lipopeptides and
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lipoteichoic acid. TLR4, on the other hand, functions mainly as a homodimer that interacts
with MD2; a co-receptor that enhances its affinity for LPS [77]. TLR4/MD2 complex recog-
nizes LPS bound to CD14; however, there is evidence that TLR4/MD2 can bind to ligands
directly [78]. Finally, endosomal TLRs 3 and 9 binds to nucleic acids; TLR3 recognises and binds
to double-stranded RNA, whereas, TLR9 recognises and binds to CpG DNA. Endosomal TLR3
and TLR4 transduce signals through the TRIF-dependent signal transduction pathway, whereas
surface TLR4 and TLR2 transduce signals through the MyD88-dependent pathway. Therefore,
TLR4 ligands activate both NF^B promoter activity and IRF3 promoter activity [79–82]. More-
over, previous research has shown that mutation of Lps2 gene locus inhibits TRIF-dependent
signalling induced by TLR4 and TLR3, thereby attenuating the production of type I interferons
and interferon-inducible proteins. Lps2 mutation reduced LPS- and PolyIC-induced TNFU pro-
duction, but PAM3CysK-induced TNFU production was not affected. Again MyD88 knockout
experiments showed that LPS-induced TNFU production was also impaired. These research
suggest that the TRIF-dependent pathway and MyD88-dependent pathway promote TNFU pro-
duction. It may also be that the Lps2 mutation impairs the LPS receptors, thereby attenuating
all downstream signals. Nonetheless, the research shows evidence that the synthesis of Type I



























































































































































































4 Microbial Molecules that Cause Inflammation
The immune system responds to microbial infection and cell damage or injury by inducing
inflammatory responses. There are several kinds of microbial pathogens; these include fungi,
viruses, bacteria, and parasites. Likewise, cell damage and cell injury refer to different kinds of
damage, for instance, cell death, DNA damage, mutation, or abnormal cell function [86].
Microbial pathogens are often the source of inflammation-causing agents known as pathogen-
associated molecular patterns (PAMP) or microbe-associated molecular patterns (MAMPs) [87].
4.1 Lipopolysaccharides
Lipopolysaccharide is an endotoxin component of the outer membrane of gram-negative bacteria.
It has three main parts: a variable O-antigen component, a core oligosaccharide [inner and
outer core], which is covalently bound to a hydrophobic “anchor” termed lipid A that typically
contains acyl tails attached to a phosphorylated V-1’,6-linked glucosamine disaccharide head
group as shown in figure 2 below. The lipid A component of LPS is the toxin that induces
inflammation through TLR4. However, lipid A can vary structurally, and this can affect its
ability to cause inflammation through TLR4 [88]. Some bacteria possess genetic mutation that
prevents the expression of the O-chain, leaving only the core region and the Lipid A region of
the lipopolysaccharide molecule; these mutations produce varying chemotypes of LPS such as
Re LPS (E. coli K12, D31m4), and Rc LPS (E. coli J5). Smooth LPS (E. coli O111: B4)
refers to the prevalent LPS which contains the O-chain. Smooth and Rough LPS may have
differential mechanisms of regulating inflammation; for instance, rough LPS may be less CD14-
dependent compared to smooth LPS [89]. CD14 and MD2 (which hosts the acyl part of lipid
A when in complex with TLR4 [90]) are known as LPS receptors. It undergoes ligand-induced
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conformational changes to activate or inhibit the LPS receptor complex appropriately. LPS-
induced activation of TLR4 induces signals that cause an increase in NF^B and IRF3 activity,
and thus the release of both pro-inflammatory and pro-resolving cytokines [91]. Researchers
have suggested that the different chemotypes of LPS have different mechanisms of inducing
inflammation. For instance, there is evidence that rough LPS is less dependent on CD14 than
smooth LPS [89].
Moreover, rough LPS from B. abortus strains of bacteria are more potent in inducing the release
of pro-inflammatory cytokines than the smooth LPS [92]. Even amongst different species, there
are differences in the potencies of LPS, for instance, rough chemotype of E. coli LPS is more
potent than the rough chemotype of B. abortus LPS [93]. Given all these differences, it will be
essential to study more about the differential mechanisms of action of rough and smooth LPS.
Figure 2: Basic Structure of Lipopolysaccharide.
Lipopolysaccharide is found on the outer membrane of gram-negative bacteria which covers the
cell wall. This diagram shows E. coli as the example of gram-negative bacteria. The three
essential parts of lipopolysaccharide that can influence its function are the O-antigen, Core
Oligosaccharide, and the Diphosphoryl Lipid A.
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4.2 Lipopeptides
Lipopeptides localise on the cell walls of several species of bacteria and fungi. They can exist
as various cyclical peptides attached to an acyl chain (e.g. lipopeptide surfactants), a tri-
palmitoyl peptide (Pam3CysK4), or a dipalmitoyl peptide (Pam2CysK4, MALP2, FSL1 – a
synthetic dipalmitoylated lipopeptide derived from M. salivarium). Tri-palmitoyl lipopeptides
(Pam3CysK4) are known to activate TLR2/1 or TLR1/6 receptor heterodimers to induce in-
flammation. Moreover, Pam3CysK4 has antiviral activity as it can activate cytotoxic T lympho-
cytes against influenza-virus activated cells [94,95]. On the other hand, dipalmitoyl lipopeptides
are TLR2/6 ligand, and they activate the MyD88-dependent pathway, thereby promoting the
production of inflammatory cytokines such as TNFU and IL6 through NF^B activation [96,97].
FSL1 induces internalisation of TLR2, enhances phagocytosis in macrophages [98], and induces
IFNV expression and secretion. FSL1 is a TLR2/6 ligand; therefore, its ability to induce IFNV
highlights a gap in understanding of the mechanism of action of FSL1 [99].
Figure 3: Chemical Structure of FSL1 created in ChemDoodle Software [1]




Bacterial and viral DNA are potent activators of natural killer cells, macrophages, and den-
dritic cells. They consist of a repeated series of unmethylated CpG motifs that bind to TLR9
homodimers, and It induces an increase in synthesis and secretion of nitric oxide and other pro-
inflammatory cytokines such as type I interferons, TNFU, and IL6. Unlike bacterial and viral
DNA, mammalian DNA has low-frequency CpG dinucleotides, and they are mostly methylated.
Therefore, mammalian DNA does not have an immune-stimulatory activity [87,100–104].
On the other hand, viral RNA can be either single-stranded or double-stranded in structure.
Differences in RNA structure can lead to differential inflammatory responses. Single-stranded
RNA is commonly recognised by TLR7 [105] and TLR8 [106], which form homodimers after activa-
tion. However, some publications [107,108] have suggested that TLR3 and NLRP3 can recognise
single-stranded RNA. TLR3 is commonly known to recognise double-stranded RNA; however,
the suggestion that it binds to single-stranded RNA from poliovirus depends on its ability to
recognise ’stem-structures’ with bulge/internal loops.
PolyIC is a synthetic double-stranded RNA, recognized by TLR3, RIG-I and MDA5. A study
suggested that RIG-I only binds to double-stranded RNA transcribed in vitro; however, an-
other study indicated that RIG-I binds to short double-stranded RNA. These studies show the
need for more understanding of how double-stranded RNA interacts with its receptors. MDA5,
on the other hand, is said to detect long double-stranded RNA without an in vitro transcrip-
tion [109–112]. PolyIC induces a high amount of type I interferons and also tumoricidal activity
in macrophages. It is also known to induce the synthesis of NF^B-dependent cytokines such
as TNFU and IL6 [113]. IRF3 is the primary transcription factor for TRIF-dependent signalling
pathway, which is responsible for the production of type I interferons. However, a study showed
that IFNV could be significantly induced in the absence of detectable IRF3 activation by trans-
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fected PolyIC through an unknown mechanism. Therefore, there is a need for more studies
to understand the mechanism of action of PolyIC. It is also noteworthy that PolyIC binds to
RIG-I, which is a known activator of both NF^B and IRF3 transcription factors. These shreds
of evidence support the ability of PolyIC to induce the transcription of TNFU [110,112,114,115].
4.4 Polysaccharides and Peptidoglycans
Microbial polysaccharides such as glucans and mannans and peptidoglycans are often found
on the cell walls of bacteria [116] and fungi [117]. TLR4, TLR2, and TLR6 can recognise micro-
bial polysaccharides [86]; however, other receptors such as mannose receptors, DC-SIGN, com-
plement receptors, and dectin receptors can recognise microbial polysaccharides and peptido-
glycans [118]. None the less, they have differential mechanisms for mediating inflammation as
aforementioned [119,120].
4.5 Proteins
Several microbial proteins are known to cause inflammation include flagellin from gram-negative
bacteria, profilin from T. gondii, and hemozoin from malaria parasite(P. Falciparum). Early
research showed that knockout of TLR5 attenuates inflammatory response to flagellin [121,122].
Flagellin can also activate inflammasome receptor, NLRC4, which activates the cleaving of pro-
IL1V by caspase 1 [123]. Moreover, similar research showed that TLR11 is specific for recognising
profilin in mice. However, this research is limited to mice rodent species as human TLR11 is
nonfunctional due to the presence of a stop codon in its gene [124]. TLR9 recognises hemozoin [125];
however, this does not directly induce an inflammatory response. Hemozoin indirectly induces
an inflammatory response by enhancing responses to DNA from malaria parasite [126].
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5 Biochemical Processes That Regulate Receptor Function
5.1 The Ubiquitin-Proteasome Pathway
Ubiquitylation of proteins plays a vital role in maintaining protein stability and as a quality
control mechanism to clear out abnormally folded and damaged proteins. It is the most common
mechanism for protein degradation for the majority of cellular proteins. However, there are
reports that the proteasome machinery degrades some non-ubiquitylated proteins [127]. The
conventional mechanism for Ubiquitin-Proteasome degradation includes two significant steps:
1. Covalent attachment of ubiquitin molecules to the target proteins
2. Degradation of ubiquitylated proteins by the proteasome
Covalent Attachment of Ubiquitin Molecules to Protein Targets.
Three classes of ubiquitin enzymes are involved in this process. These include; the E1 ubiquitin-
activating enzymes, the E2 ubiquitin-conjugating enzymes, and the E3 ubiquitin ligases. Ac-
cording to reports, only two genes encode for the E1 ubiquitin-activating enzymes, about 100
genes encode the E2 ubiquitin-conjugating proteins, and over 1000 genes encode for the E3
ubiquitin ligases. The many combinations made with E2 ubiquitin-conjugating enzymes and
E3 ubiquitin ligases account for the high specificity of the protein ubiquitylation [128]. In innate
immunity, various E3 ubiquitin ligases participate in regulating TLR signalling. Nrdp1 ubiqui-
tylates MyD88, a common TLR adapter molecule, and targets it for degradation [129]. TRAF6
is also an E3 ubiquitin ligase that is essential for MyD88-dependent and TRIF-dependent TLR
signalling [130]. Other E3 ubiquitin ligases that regulate TLR signalling include Triad3A and
Pelle-interacting proteins [131,132]. Ubiquitylation of NF^B p50 subunit negatively regulates its
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function. Moreover, the translocation of NF^B to the nucleus, where it transcribes inflam-
matory cytokines in response to TLR activation, is highly dependent on the ubiquitination of
IKK proteins which are bound to NF^B to keep it in the cytosol [128,133]. Other functions of
ubiquitylation that may indirectly influence TLR signalling involves;
• Monoubiquitylation which triggers internalization of cell surface proteins through the en-
docytic pathway [128]
• Sourcing of amino acids for protein synthesis [134]
• Negative regulation of RIG-I helicases by RNF125 (an E3 ubiquitin ligase) [135]
• Antigen presentation by MHC class I molecules [128]
Degradation of Ubiquitylated Proteins By The Proteasome.
There are two significant types of proteasome machinery: the 20S proteasome and the 26S pro-
teasome. The 26S proteasome is the most massive proteasome machinery that consists of two
19S subunits and one 20S subunit [127,136]. There are implications of a role for the ubiquitin-
proteasome pathway in some pathologies. For instance, the stability of p53 (a significant reg-
ulator of cell cycle and tumour suppressor) is highly dependent on the ubiquitin-proteasome
machinery. Furthermore, the process of ubiquitination is said to contribute to oxidative stress in
cells; this results in COPD and other inflammatory diseases. Finally, the Ubiquitin-Proteasome
machinery can be hijacked by viruses to degrade vital cellular proteins that fight viral infec-
tions [127,137–139].
5.2 Post-Translational Modification
Protein phosphorylation refers to the addition of phosphate groups to amino acid residues of
proteins by kinases. The specific amino acid residues to be phosphorylated are often; Serine,
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Threonine, and Tyrosine. Phosphorylation of TLRs occur on their tyrosine residues, and this
activates their interaction with adapter proteins. Moreover, there is evidence that stimulation
of macrophages with LPS induces various phosphorylation activities. For instance, LPS induces
phosphorylation by IRAK1. IRAK1 then phosphorylates a negative regulator of TLR-MyD88
signalling, Tollip, allowing the action of TRAF6 which is essential for the downstream signalling
of the TLR-MyD88 pathway. IRAKs are also known to associate with MyD88 directly through
its death domain [140,141]. PI3 kinases are also essential regulators of TLR signalling. This Ser-
ine/Threonine kinase is critical for the activation of transcription factors that are downstream of
the TLR signalling pathway [140,142]. Knockout of MyD88 resulted in enhanced phosphorylation
of IRF3, which led to increased production of IFNV. Finally, inhibition of MNK kinases which
are downstream of TLR/ERK/MAPK signalling pathway attenuated the production of TNFU
in macrophages [143,144]. These reports are evidence of the critical role of phosphorylation in
TLR signalling in macrophages and other cell types.
5.3 Endocytic Pathway
Endocytosis refers to the internalization of cell surface proteins by specialized lipid vesicles en-
riched with PI3 kinases known as endosomes. Endocytosis is a regulator of signal transduction
and is responsible for controlling the abundance of functional receptors on the cell surface. En-
docytosis also contributes to viral infections as some viruses require an active clathrin-dependent
endocytic pathway for successful infection [145–148]. Lipid rafts function as platforms for internal-
isation and early endosomal sorting functions. They are nano-sized dynamic membrane enriched










































































































































































5.4 Phospholipid Membrane Remodelling
Lands cycle, also known as the phospholipid remodelling pathway defines the liberation and
esterification of fatty acyl moieties into phospholipid pools. The general functions of phospholipid
remodelling include;
• An efficient source of energy [150]
• Generation of membrane diversity and asymmetry [150]
• Post-translational lipid modification of proteins [150,151]
• Synthesis of lipid mediators of inflammation, such as PAF, leukotrienes, and eicosanoids [150,152]
In lands cycle, a pre-formed phospholipid is acted upon by intracellular phospholipase A to
generate a lysophospholipid which is later re-acylated by Acyl CoA-dependent acyltransferases.
LPCATs play an essential role in the remodelling of phosphatidylcholine, which makes up the
majority of cell membranes. Moreover, the only acyltransferases that are known to participate
in the synthesis of the lipid mediator, PAF, are LPCATs 1 and 2 [150,151,153]. The abundance of
arachidonic acid during inflammation in macrophages, which is one of the essential fatty acids
used in the Lands cycle, is dependent upon the relative activity of reacylation and deacylation
of phospholipids. Stimulation of macrophages with TLR ligands is also known to stimulate
changes in phospholipid components of the macrophage membrane by activating the activity of
phospholipid remodelling enzymes [154–156].
5.5 Lipid Raft Microdomains
Lipid rafts are dynamic liquid-ordered micro-domains of the cellular plasma membrane en-
riched in cholesterol and glycosphingolipids [157] and resistant to extraction with non-ionic de-
tergents [158–160]. Lipid rafts participate in membrane transport [160] and signal transduction.
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Previous research has shown that lipid rafts are essential for virus entry through endocyto-
sis [158]. There are also suggestions that lipid rafts regulate signal transduction by preventing
protein-protein interactions or by suppressing the intrinsic activity of signalling proteins [159].
LPCAT2 (which is vital for membrane phospholipid remodelling) regulates the translocation of
TLR4 to the lipid raft where it dimerises and transduces signals; as a result, knock-down of
LPCAT2 reduces TLR4 signalling [161].
6 Mediators of Inflammation and Their Systemic Effects
The signs of inflammation were first identified as pain, redness, swelling, heat, and loss of function
in the inflamed area by Aulus Cornelius Celsus and Rudolf Virchow [162,163]. Except for the loss
of function and fever, the other symptoms of inflammation are caused by excessive dilation of
the blood vessels (redness), increased blood flow (heat), and accumulation of fluid outside blood
vessels (swelling) [2]. Moreover, activation of immunocytes and the excessive release of molecules
such as interleukins, tumour necrosis factors, interferons, chemokines, reactive oxygen species,
and lipid mediators are the cause of these symptoms [164,165].
6.1 Cytokines and Chemokines
There are up to 40 subtypes of interleukins, and they play various roles that contribute to
inflammation. Interleukins are synthesised and secreted by many immunocytes. They can induce
the release of other pro-inflammatory cytokines (IL1U, IL1V, IL17, IL23, IL25, IL31, IL32), the
activation, differentiation, and proliferation of immunocytes (IL1U, IL1V, IL2 – IL7, IL9, IL12,
IL14, IL15, IL21, IL34, IL35), wound healing and repair (IL5, IL22), tumour suppression (IL24),
and antiviral immunity (IL28, IL29). Furthermore, some interleukins function as chemokines
(they attract the migration of immunocytes to the site of inflammation– IL8, IL16), and some
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are pro-resolving cytokines (IL10, IL37) [166]. Interleukin 1 can also induce fever by stimulating
the hypothalamus [167].
TNFU is a common biomarker for various inflammatory diseasesbecause of large amounts of
TNFU secreted during inflammation [168]. Like some interleukins, TNFU induces maturation
and differentiation of macrophages and dendritic cells [169]. It also induces the synthesis and
secretion of other inflammatory mediators by binding to its receptor, which eventually activates
NF^B [170].
Interferons have three classes; Type I includes IFNU, IFNV, IFNl, IFN^, and IFNn , Type II
consists only of IFNW, and Type III includes IFN_1, IFN_2, IFN_3 [171]. Interferons mainly
participate in antiviral immunity; however, they also attenuate cell proliferation and induce the
expression of other inflammatory mediators such as Nitric Oxide Synthase (NOS) and IFN-
inducible Protein 10 (IP10 also known as CXCL10) [171,172].
6.2 Reactive Oxygen and Nitrogen Species
Nitric Oxide, Hydrogen peroxide, and Superoxide are examples of reactive oxygen and nitrogen
species. Most of the reactive species are more commonly known to participate in cell damage
or cell death [173]. However, Nitric Oxide and its synthases participate in inflammation. Several
publications have demonstrated that lipopolysaccharide (an inflammatory agent) induces the
expression of Nitric Oxide and inducible Nitric Oxide Synthase (iNOS) [174–177]. Nitric oxide
contributes to vasodilation, as it is a second messenger for vasodilators [178,179]. As mentioned
earlier, vasodilation is a hallmark of inflammation as it causes redness and heat due to increased




Leukotrienes and prostaglandins (prostacyclin and thromboxane A2) are potent enhancers of
innate and adaptive immunity. However, Lipoxins and prostaglandins (PGE2, PGD2) participate
in resolving inflammation [181,182]. Both prostaglandins and leukotrienes are by-products of the
oxidation of arachidonic acid carried out by cyclooxygenases (COX1, COX2). Arachidonic acid
is also a by-product of membrane phospholipid remodelling pathway where phospholipase A2




















































































































































































































































































































































































A Literature Review on LPCAT2 and Its
Importance in Macrophage Inflammatory
Responses
LPCATs consists of four subtypes, LPCAT1, 2, 3, and 4. They are key participants in mem-
brane phospholipid remodelling. LPCAT3 localises ubiquitously, whereas LPCAT4 localises in
the brain and reproductive organs. LPCAT3 shares the same preference for arachidonoyl-CoA
as LPCAT2; however, the most structurally similar LPCAT to LPCAT2 is LPCAT1 [156]. Un-
like LPCAT1, LPCAT2 is highly expressed in inflammatory cells such as resident macrophages
and can be induced by LPS but not by PolyIC [150,156]. LPS and other TLR agonists stimu-
late phosphorylation of LPCAT2 on the Serine 34 residue [192]. In the same vein, ATP induces
rapid phosphorylation of LPCAT2 after 15-30 minutes [193]. Previous research suggests that
the phosphorylation of LPCAT2 is highly dependent on MK2 because TAK1 inhibitors and
p38 MAPK inhibitors attenuated the level of phospho-LPCAT2 and phospho-MK2. The pH
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range for maximum LPCAT2 activity is between 5.5 and 7.5. Therefore, pH is another factor
that can affect LPCAT2 function, just as it would affect other enzymes [194,195]. LPCAT2 has
both acyltransferase and acetyltransferase activity and is also known as LysoPAFAT (lysoPAF
acetyltransferase). In basal conditions, LPCAT2 has a higher affinity for arachidonoyl-CoA for
its acyltransferase activity. However, when LPS activates it, it uses Acetyl-CoA more efficiently
for its acetyltransferase activity to produce PAF (Platelet Activating Factor), which is a lipid
inflammatory mediator [196]. Calcium and magnesium ions inhibit LPCAT2 activity [197]. LP-
CAT2 localises in the endoplasmic reticulum and on lipid droplets. It has the EF hand-like
and KKXX motifs which is essential for its activity and localisation in the endoplasmic reticu-
lum [150,156,192,193]. Lipid modifying enzymes like LPCAT2 can control the assembly of the LPS
receptor complex in the lipid raft. Results that showed that the inhibition of LPCAT reduced
LPS-induced inflammatory response by preventing the translocation of TLR4 into the lipid raft
support this statement [198]. In inflammatory disorders such as sepsis and allergic asthma, LP-
CAT2 has been suggested as a biomarker [191,199]. There is yet no full understanding of the
molecular mechanisms of the influence of LPCAT2 in inflammation. Understanding the molecu-
lar mechanisms of LPCAT2 may, therefore, be a key that will unlock a novel method of handling
inflammation. Protein post-translational modification influences inflammatory processes [200,201].
Moreover, LPCAT1 has been shown to co-localise with histone 4 in the nucleus and palmitoy-
late the protein; eventually affecting its transcriptional activity [202]. Our lab has also shown
that LPCAT2 acylates proteins, and some of these proteins are involved in inflammatory pro-
cesses [203]. These pieces of evidence imply that post-translational modification of proteins by
LPCAT2 may participate in inflammation, particularly TLR4 signalling. LPCAT2 is known for
two activities [acylation and acetylation]. If LPCAT2 acylates proteins, it is also possible that it
can acetylate proteins. Moreover, LPCAT2 has been shown to co-localise with TLR4 to regulate
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LPS-induced inflammatory gene expression [161]. How LPCAT2 regulates TLR4 signalling is yet
to be understood, and acetylation of TLR4 or its co-receptors or its co-signalling proteins could
be one of the ways that LPCAT2 regulates TLR4 signalling.
LPCAT2 influences inflammation by influencing the expression and function of toll-like re-
ceptors. Inhibition of LPCATs prevents TLR4 signalling by preventing translocation of TLR4 to
the lipid raft which is essential for signalling [161,204]; this results in suppression of TNFU and IL6
expression. LPCAT2 silencing has a similar effect as it suppresses the expression of TNFU and
IL6, and the production of PAF – a pro-inflammatory lipid in both LPCAT2 knockout mice and
isolated peritoneal macrophages [205,206]. These findings have led to the question of "How LP-
CAT2 regulates macrophage inflammatory responses?". The primary mediators of inflammation
in macrophages are the TLRs; therefore, any alteration in the expression or function of a TLR
will change all downstream signalling. It is therefore plausible to hypothesise that LPCAT2
regulates inflammation by modifying the abundance and function of receptors of inflamma-
tory ligands such as TLRs. CD14 is an essential co-receptor for LPS-mediated inflammation.
Researchers have previously shown that CD14 knockout reduces LPS (mostly smooth LPS) sig-
nalling [205,206]. Since inhibition of LPCATs also reduce LPS signalling [198], it is plausible to
assume that LPCAT2 silencing might reduce the expression of CD14, and hence, attenuate LPS
signalling. Post-translational modifications regulate inflammation. Most commonly, ubiquityla-
tion and phosphorylation [207]. However, various kinds of protein acylation regulate localization,
stability, and protein-protein interactions of proteins; acylation and acetylation control TLR2
and other inflammatory proteins such as RelA and IRFs 3 and 7 [208]. LPCAT2 is known to carry
out fatty acylation of lipids [187,188]. Moreover, previous research from our lab showed that LP-
CAT2 silencing reduced the LPS-induced palmitoylation of proteins, suggesting that LPCAT2
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influences fatty acylation of proteins. TLR4 was not one of the palmitoylated proteins, but
LPCAT2 co-localizes with TLR4 [161]. The role of LPCAT2 during TLR4-LPCAT2 interaction is
unclear. However, since LPCAT2 is an acetyltransferase and TLR4 was not amongst palmitoy-
lated proteins in the previous research, it is possible that the LPCAT2 influences the acetylation
of proteins, and that TLR4 could be one of the acetylated proteins. Acylation is responsible
for regulating protein stabilization [209]. For instance, the deacylation of proteins is one of the
mechanisms for targeting proteins to the ubiquitin-proteasome pathway for degradation [210,211].
Previous data from our lab showed that LPCAT2 silencing reduced the LPS induced acylation
of RNF19B [203]. However, its influence on RNF19B expression and function is not known. Here,
the impact of LPCAT2 on RNF19B abundance and function is studied. Toll-like receptors share
a similar structure and mechanism of signalling [212]; therefore, the influence of LPCAT2 on







• RIPA Buffer: 20mM Tris-HCl [Fisher BioReagents; 10053023, 10103203] (pH 7.5),
150mMNaCl [Fisher BioReagents, 10112640], 1mM EDTA [Sigma-Aldrich, E9884], 1%(v/v)
V-mercaptoethanol [Sigma-Aldrich, M3148], 1%(w/v) sodiumdeoxycholate [Sigma-Aldrich,
30970].
• Denaturing Solution for Total RNA Extraction: 4M Guanidinium Thiocyanate
[Fisher BioReagents, 10285253], 0.75M Sodium Citrate Dihydrate(pH 7.0) [Fisher BioRe-
agents, 10797024], 10%(w/v) N-Laurosylsarcosine (Sarkosyl) [Fisher BioReagents, 10698963],
0.72%(v/v) V-mercaptoethanol.
• Phosphate Buffered Saline [Gibco by Life Technologies, 18912014]
• ELISAWash Buffer: Phosphate Buffered Saline/0.05% Tween-20 [Sigma-Aldrich, P1379].
• Tris Buffered Saline: 50mM Tris-Base(pH 7.5) [Fisher BioReagents, 10103203], 150mM
NaCl, 1mM EDTA.
• Western Blot Wash Buffer: Tris Buffered Saline/0.1% Tween-20.
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• ECL Detection Reagent: 20mM Tris-HCl (pH 7.5), 250mM Luminol [Sigma-Aldrich,
A8511], 90mM p-Coumaric Acid [Sigma-Aldrich, C9008], Hydrogen Peroxide (1:2500)
[Sigma-Aldrich, 216763].
• Western Blot Blocking Buffer: 5% Bovine Serum Albumin [Sigma-Aldrich, 05470] in
Tris Buffered Saline.
• ELISA Blocking Buffer: 2% Bovine Serum Albumin in Phosphate Buffered Saline.
• Culture Medium: DMEMwith 2.5g/l Glucose [Lonza, BE12-914F], 1% 0.2M L-Glutamine
[Lonza, BE17-605E], 10% Foetal Bovine Serum [Labtech.com, BS-110].
• Freeze medium: Culture Medium with 20%(v/v) DMSO [VWR International, J66650].
• Staining Buffer: 5% Foetal Bovine Serum in Phosphate Buffered Saline.
• Cell Lysis Buffer: 1%(v/v) Triton X-100 [Fisher BioReagents, 10102913] in Tris Buffered
Saline.
• Tris-V-Octylglucoside Buffer: 60mM V-Octylglucoside [Sigma-Aldrich, O9882].
• Mild Elution Buffer: 187.5mM Tris-HCl(pH 6.8), 6%(w/v) SDS [Fisher Scientific,
10593335], 30%(v/v) Glycerol [Sigma-Aldrich, G5516], 0.03%(w/v) Bromphenol blue [Sigma-
Aldrich, B0126].
• Harsh Elution Buffer: 187.5mM Tris-HCl(pH 6.8), 6%(w/v) SDS, 30%(v/v) Glycerol,
0.03%(w/v) Bromphenol blue, 100mM V-mercaptoethanol.
• SDS Sample Buffer: 187.5mM Tris-HCl(pH 6.8), 6%(w/v) SDS, 30%(v/v) Glycerol,
0.03%(w/v) Bromphenol blue, 100mM V-mercaptoethanol.
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• Antibody Stripping Buffer: 6M Guanidinium Hydrochloride [Fisher BioReagents,
10071503], 0.2%(v/v) Triton-X100, 0.1M V-mercaptoethanol, 20mM Tris-HCl(pH 7.5).
• Staining Buffer: PBS solution, 2%(w/v) Bovine Serum Albumin.
• Resolving Buffer: 1.5M Tris-HCl buffer(pH 8.8).
• Stacking Buffer: 0.5M Tris-HCl buffer(pH 6.8).
• Novex Tris-Glycine SDS Running Buffer (10x) [Invitrogen by Life Technologies,
LC2675].
• Novex Tris-Glycine Transfer Buffer (25x) [Invitrogen by Life Technologies, LC3675].
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Chapter 5
Culturing, Transfection, and Stimulation
of RAW264.7 cells
Figure 6: Monitoring RAW264.7 cells Using Inverted Microscope.
Cells were regularly monitored by checking for any signs of infection or stress such as clumping.
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RAW264.7 cell line was obtained from the European Collection of Cell Cultures (ECACC)
through the Health Protection Agency (HPA), UK. RAW264.7 cells were maintained by renewing
the culture medium every 2-3 days. The cells were passaged every 4-5 days consistently, and
they were usually about 70% confluent on these days.
1 Cryopreservation
RAW264.7 cells were cryopreserved in freeze medium (2 ∗ 106 cells/ml). The cells were imme-
diately stored at ≤ -80ºC using a cryofreezing container to achieve the optimal 1ºC/minute
freezing rate for cells [213]. The cells were later transferred to regular freezing boxes and stored
at -80ºC until needed.
2 Thawing
A cryovial of RAW264.7 cells was thawed and immediately transferred into a tube containing
10ml complete medium. The tube containing the thawed cells were centrifuged at 160g for
5 minutes. The supernatant was discarded, and the cells were re-suspended in 5ml complete
medium. The cells were transferred to a 25cm2 tissue culture flask and incubated at 37ºC,
5% CO2 overnight. The culture medium was changed the following day. When the cells had
reached 70 – 80% confluence, they were scraped off, centrifuged, and resuspended in 10ml culture
medium. They were then transferred to a 75cm2 flask and incubated at 37ºC, 5% CO2.



























































































































































































RAW264.7 cells were scraped and resuspended in 8ml medium. To reduce the concentration,
10`l of cells were further resuspended in 30`l culture medium. Then, 10`l of a 1:2 mixture
of filtered trypan blue [Sigma-Aldrich, T6146] and cells was pipetted into a haemocytometer
[Marienfeld, 0640111]. The total number of cells in each 1mm2 square of the haemocytometer
was counted, and the average was taken. Cells that took up trypan blue were counted as dead
cells. The values were used to calculate cell concentration and viability.
4 Gene Silencing: RNA Interference using siRNA
RNA interference is a technique used for gene silencing in in vitro experiments. It is often
mediated by Short hairpin RNAs (shRNAs), small interfering RNAs (siRNAs), and microRNAs.
However, microRNAs are non-specific because they silence multiple targets. shRNAs and siRNAs
are specific; however, it is easier to transfect siRNAs into cells than shRNAs [214–216].
RAW264.7 cells were transiently transfected with 7nM of siRNA (Silencer Select Pre-Designed,
Ambion by Life Technologies, 4390815 - LPCAT2(s114512), 4390771 - RNF19B(s93353), AM16708
- TLR4, 4390843 - Negative control(s114512)). Transfection duplexes contained 7nM siRNA,
and 5.7%(w/v) INTERFERin transfection reagent [PolyPlus transfection, 409-10] in Opti-MEM
(Reduced Serum Medium) [Gibco by Life Technologies, 31985070]. Transfection was typically
carried out in 6-well plates or 25cm2 tissue culture flasks. The macrophages were incubated in
a humidified incubator 37ºC with 5% CO2 for 48 hours. Then the medium was changed before
stimulating the cells.
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5 Ligand Reconstitution and Storage
5.1 Lipopolysaccharide (LPS)
Lipopolysaccharide was prepared in high concentrations with LAL grade reagent water (<0.005EU/ml
endotoxin levels) [Lonza, W50-640] in a sterile condition. Sub-stocks of 10mg/ml were made and
stored at -20ºC in pyrogen-free glass tubes. To prevent freeze-thaw cycles, the sub-stock that is
used frequently is stored at 4ºC for a month.
5.2 Fibroblast Stimulating Ligand 1(FSL1)
FSL1 was reconstituted in LAL grade reagent water at 10mg/ml and stored long term at -20ºC.
Working concentrations (1–100ng/ml) were prepared from stock concentration using culture
medium. Working concentrations were stored at 4ºC for 2–4 weeks.
5.3 PolyIC
PolyIC was reconstituted in nuclease-free water at a concentration of 1g/ml and stored at -
20ºC. Working concentrations (1–100`g/ml) were prepared from stored stocks using nuclease-
free water to prevent degradation, and the concentrations were confirmed by measuring the RNA
with Nanodrop2000. Working concentrations were stored at -20ºC and used only three times.
6 Cell Stimulation
RAW264.7 macrophages were stimulated with 100ng/ml E. coli O111:B4 [Sigma-Aldrich, L260],
J5 [List Biological Laboratories, 301], and K12, D31m4 [List Biological Laboratories, 302] LPS
for various durations to analyse the effect of LPCAT2 and RNF19B silencing on the expression
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of target genes and proteins. Similarly, 1 – 100ng/ml FSL1 [Invivogen, tlrl-fsl] and 1 – 100`g/ml




1 Sample Preparation for Rapid Lipid Raft Isolation
After LPS-stimulation, the medium containing stimulant was removed. The cells were rinsed
twice with ice-cold PBS, scraped in PBS, and transferred into microfuge tubes. The collected
sample was centrifuged at 200xg for 5 minutes. The supernatant was discarded, and cells were
resuspended in Tris buffer. The cells were then passed through HGM ball-bearing Whole-cell
cracker with an 8.012mm ball [161]. After another round of centrifugation at 500xg for 5 minutes,
the supernatant (the cytosolic fraction) was separated and used immediately or stored at -20ºC
for future use in isolating lipid raft fractions.
2 Sample Preparation for Total RNA Isolation
After stimulation of cells with LPS, FSL1, or PolyIC, the medium containing stimulant was
removed. The cells were lysed in Denaturing buffer. RNA Isolation procedure was carried out
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immediately or stored at -20ºC.
3 Sample Preparation for Enzyme-linked Immunosorbent
Assay (ELISA)
After stimulation of cells with LPS, FSL1, or PolyIC, the supernatants were collected for ELISA
by pipetting into clean microfuge tubes. The supernatants were centrifuged at 200xg for 5
minutes to separate dead cells from the supernatant. The new supernatant was then separated
into another clean tube in aliquots and stored at -20ºC for carrying out ELISA.
4 Sample Preparation for Immunoprecipitation
After stimulation of cells with LPS, the medium was discarded, and the cells were rinsed with
ice-cold PBS. Then the cell lysis buffer was added. The macrophage lysate was scraped off and
transferred to a microfuge tube. Sonication at 4ºC was used to break down DNA fragments. The
lysates were centrifuged at 20, 000xg for 10 minutes, and the supernatant was used immediately
for immunoprecipitation
5 Sample Preparation for Gel Electrophoresis and Immunoblot-
ting
After stimulation of cells with LPS, the medium containing the stimulant was removed. The cells
were rinsed twice with ice-cold PBS, then cold RIPA buffer was added to the cells. The cells were
left on ice for 30 minutes, after which the lysate was scraped and collected into microfuge tubes.
The lysates were sonicated (in a cold room, on ice) 3 times for 10 seconds with 30 seconds
54
interval between each sonication. Sonication was carried out to break down DNA molecules
which may interfere with Gel electrophoresis or immunoblotting. Furthermore, the lysates were
centrifuged at 20, 000xg for 10 minutes to separate undissolved proteins, DNA fragments, dead
cells, or intact cells. The supernatant was collected into a clean microfuge tube and either used
immediately or stored at -20ºC for future use.
6 Sample Preparation for Flow Cytometry
After stimulation with LPS, the cells were rinsed twice with ice-cold PBS, scraped, and resus-




Analysis of mRNA Expression
1 Total RNA Isolation and Quantitation
The total RNA isolation procedure was adopted from [217], with minor modifications. Chloroform
was replaced with Bromochloropropane for the formation of liquid interphase. Total RNA was
isolated by first adding 50`l of sodium acetate [Fisher BioReagents, 10794761], 500`l of water-
saturated phenol [Fisher BioReagents, 10458074], and 100`l of bromochloropropane [Sigma-
Aldrich, B9673] to the cell lysate. The mixture was shaken thoroughly for 10 seconds and kept
on ice for 15 minutes. Centrifugation at 15, 000xg for 20 minutes at 4ºC was used to separate
the aqueous phase from the non-aqueous phase. Isopropanol [Sigma-Aldrich, 278475] was added
to the aqueous phase to precipitate RNA, and this mixture was stored at -20ºC for at least
one hour. After precipitation of RNA, the mixture was centrifuged at 15, 000xg for 20 minutes
at 4ºC. The RNA precipitate was resuspended in 300`l of denaturing buffer and mixed with
300`l of Isopropanol. The mixture was incubated at -20ºC for at least 30 minutes. This step
was for purification of the RNA. The incubated mixture was centrifuged at 15, 000xg for 10
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minutes at 4ºC to remove any residual guanidinium thiocyanate. The RNA precipitate was then
resuspended in 75% Ethanol [Fisher BioReagents, 10517694]. The purified RNA was either used
immediately or stored at -20ºC for future use. In order to remove any residual DNA, total RNA
was treated with DNase I using a DNase I amplification kit according to manufacturer’s protocol
[Sigma-Aldrich, AMPD1]. The purified RNA was centrifuged at 15, 000xg for 10 minutes at
4ºC. The ethanol was discarded, and the RNA precipitate was left to dry. Total RNA was
quantified using NanoDrop2000 [ThermoFisher Scientific, UK]; the purity was estimated using
the A260/A280 ratio.
2 cDNA Synthesis
500ng - 1`g of RNA was reverse transcribed to complementary DNA using a High Capacity
RNA to DNA kit [Applied Biosystems by Life Technologies, 4387406]. The reverse transcription
master mix contained 10% Reverse Transcriptase and 90% Buffer. The RNA samples were
mixed with the master mix in a 1:2 ratio. The mixture was incubated in Veriti thermal cycler
[Applied Biosystems, UK] at 37ºC for 60 minutes to activate reverse transcriptase activity, and
the transcribed complementary DNA was separated from the mRNA by heating to 95ºC for 5
mins. The sample was then cooled at 4ºC and stored at -80ºC for future use. The buffer from the
reverse transcription kit contained Oligo dT primers which prime all mRNA by binding to the
poly-A tail on the 3’ of the mRNA. Thus increasing the specificity of the reverse transcriptase
for mRNA [218].
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3 Real-Time Quantitative Polymerase Chain Reaction (RT-
qPCR)
PCR primers were designed with Primer3 Plus Bioinformatics Software and NCBI BLAST.
RT-qPCR was carried out using Power SYBR Green PCR master mix [Applied Biosystems
by Life Technologies, 10658255]. cDNA was diluted five times with nuclease-free water. The
PCR master mix contained 37%(w/v) nuclease-free, 230nM of target primers (a mixture of both
forward and reverse primers), and 60%(w/v) Power SYBR Green master mix. The 96-well PCR
plate was loaded with 9`l of PCR master mix and 3`l of diluted cDNA, then sealed for PCR
run. RT-qPCR run was carried out using the StepOne Plus Real-Time PCR instrument [Applied
Biosystems by Life Technologies, UK]. The stages of the run include; Activation of Polymerase
by incubation at 95ºC for 10 minutes, then 40 repeated cycles of Denaturing for 15 seconds
at 95ºC, annealing and extension for 60 seconds at 60ºC. The melt curve for each primer was
obtained to estimate the purity and feasibility of the primers. GAPDH and ATP5B were used
as endogenous controls [219]. No template controls were also included in the experiments. The
data from the run was collected in xslx format for data analysis.
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Chapter 8
Analysis of Protein Expression
1 ELISA
Each well of 96 well NUNC high bind ELISA plates [Greiner BioOne, UK] was filled with 100`
l of the appropriate concentration of capture antibodies [IL6 – EBioscience, 14-7061-81; IP10 –
Peprotech, 500-P129; TNFU – EBioscience, 14-7423-81] in PBS and incubated at 4ºC overnight.
Unbound antibody was washed off using the wash buffer, and then each well was filled with 300`l
of blocking buffer and left at room temperature for 1 hour. While the plates were incubating,
a 1:2 serial dilution of recombinant protein standards [IL6 – EBioscience, 29-8061-65, TNFU
– EBioscience, 14-8231-63, IP10 – Peprotech, 250-16] were prepared (0 - 2000pg/ml) in PBS.
Samples were also diluted if necessary. After incubating the plates with blocking buffer, the
plates were washed. Then 100`l of standards and samples were added to corresponding wells.
The plate was incubated overnight at 4ºC. Samples were discarded after incubation, and the plate
was washed three times. Then 100`l of 500ng/ml biotinylated antibodies [IL6 – EBioscience,
13-7062-81; IP10 – Peprotech, 500-P129; TNFU – EBioscience, 13-7326-81] diluted in blocking
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buffer were added to each well and incubated for 2 hours at room temperature. The unbound
antibodies were washed away by washing three times with wash buffer, then 100`l of diluted
horseradish peroxidase-conjugated avidin [ThermoFisher Scientific, 18-4200-93] was added and
incubated at room temperature for 30 minutes. After 30 minutes, the plates were washed three
times, and 100`l of Super Aqua Blue substrate [Invitrogen by ThermoFisher Scientific, 00-4203-
56] was added to wells. After colour development, the absorbance was measured at 405nm using
a microplate reader [BMG Labtech, UK]. The data was then collected for further analysis.
2 Rapid Lipid Raft Isolation
The rapid lipid raft isolation procedure was adopted from [220]. Samples were centrifuged at
20,000xg for 30 minutes, the supernatant (the cytosolic fraction) was separated and stored at
-20ºC. The pellet (containing plasma membrane) was resuspended in 200`l cell lysis buffer and
incubated on ice for 30 minutes. After incubation, the resuspended pellets were centrifuged at
16, 000xg for 20 minutes. The supernatant (the non-raft membrane fraction) was separated and
stored at -20ºC. The pellet (raft membrane fraction) was resuspended in Tris-V-Octylglucoside
buffer and incubated on ice for 30 minutes. The protein concentrations (mg/ml) for each fraction
was determined before using them for gel electrophoresis.
3 Protein Quantitation
All protein quantification was carried out using the Bicinchoninic Acid Assay kit [ThermoFisher
Scientific, 23227] following the manufacturer’s protocol. Bovine serum albumin was diluted in
ice-cold PBS and used as standards (0 – 200`g/ml). Samples were diluted at least 20 fold with
ice-cold PBS. 50`l of samples and standards were added to corresponding wells in duplicates.
60
The plate was then incubated at 37ºC for 1 – 2 hours. The plate was then read at 562nm.
4 Immunoprecipitation
Lysates were pre-cleared by incubating with Protein A/G Agarose beads [Santa Cruz Biotech-
nology, sc-2003] (rinsed with PBS) and Normal IgG [Santa Cruz Biotechnology, sc-2025, sc-2027]
for 1 hour at 4ºC. The pre-cleared lysates were then incubated with target antibodies [Cell Sig-
nalling Technologies; Rabbit Anti-Mouse Acetylated Lysine - 9441, Rabbit Anti-Mouse TLR4 -
14358] overnight at 4ºC. The following day, Protein A/G Agarose beads (rinsed with PBS) was
added to the antibody-tagged lysates and incubated overnight at 4ºC. The tubes were kept on
a tube rotator during all incubation steps. After incubation, protein A/G agarose beads were
precipitated by centrifugation at 1000xg for 5 mins. The supernatant was separated, and the
beads were washed twice with PBS. 20`l of Mild Elution buffer was then added to the beads
and incubated for 10 minutes at 50ºC. The elute separated from the beads during centrifugation
at 1000xg for 5 mins. 20`l of SDS Harsh Elution Buffer was then added to the beads, and
the beads were boiled at 95ºC for 5 minutes. The elute separated from the beads again during
centrifugation at 1000xg for 5 minutes. Both mild elute and harsh elute was combined and used
for gel electrophoresis.
5 Gel Electrophoresis
SureCast gel hand-cast system [ThermoFisher Scientific, HC1000SR] was used to prepare tris-
glycine agarose gels following the manufacturer’s protocol. Resolving gels were cast by mixing
2ml of 40%(w/v) Acrylamide solution [Invitrogen by ThermoFisher Scientific, HC2040], 2ml
of resolving buffer, 3.9ml of distilled water, 80`l of Ammonium persulphate [Invitrogen by
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ThermoFisher Scientific, HC2005], and 8`l of TEMED [Invitrogen by ThermoFisher Scientific,
HC2006]. Stacking gels were cast by mixing 300`l of 40% Acrylamide solution, 750`l of stacking
buffer, 1.92ml of distilled water, 30`l of Ammonium persulphate, and 3`l of TEMED. 10% Tris-
Glycine gel stacked with 4% Tris-glycine gel was used for gel electrophoresis. Protein samples
were diluted to equal concentrations in SDS sample buffer and heated at 95ºC for 3 mins before
loading onto gels. Electrophoresis was carried out at 125V for 2 hours at room temperature
in electrophoresis tanks filled with 1x running buffer. The samples were run alongside Biotin-
labelled protein ladders [Cell Signalling Technologies, 14208S] and colour-coded protein ladders
[Cell Signalling Technologies, 7727S].
6 Western Transfer
After gel electrophoresis, proteins were transferred to activated PVDF membranes. PVDF
membranes [GE Life Sciences, UK] was activated in absolute methanol for 30 seconds. Then
the membrane was rinsed twice with distilled water and soaked in 1X transfer buffer containing
10% absolute methanol [Fisher BioReagents, 11480520] for at least 10 minutes, along with filter
paper and blotting pads [Fisher Scientific, UK]. The gel was covered with a filter paper and
placed on pre-soaked blotting pads. The uncovered surface of the gel was covered with the
PVDF membrane, and then a filter paper was placed on it along with pre-soaked blotting pads.
The transfer cassette was closed tightly and placed in an electrophoresis tank; the tank was filled
with 1X transfer buffer containing 10% methanol. The protein transfer was carried out at 25V
for at least 2 hours at 4ºC.
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7 Blotting Procedure
Table 2: List of Antibody Dilutions Used for Immunoblotting
Antibody Conjugation Dilution Source




None 1: 1000 Sigma Aldrich[T6793]
Anti-Goat IgG HorseRadish Peroxidase 1: 1000 Santa Cruz
Biotechnology[sc-2020]
Anti-Mouse IgG HorseRadish Peroxidase 1: 1000 Santa Cruz
Biotechnology[sc-358914]
Anti-Rabbit IgG HorseRadish Peroxidase 1: 1000 Cell Signalling Technol-
ogy[7074]




None 1: 500 Santa Cruz
Biotechnology[sc-32233]








None 1: 1000 Fisher Scien-
tific[15799811]
Mouse Monoclonal TLR4 None 1: 500 Santa Cruz
Biotechnology[sc-293072]
These dilutions were recommended in the data sheet from the manufacturers.
Before dot blotting, proteins were diluted in PBS to make all concentrations equal. 1`l of
proteins were dotted onto the nitrocellulose membrane and left to dry at room temperature.
For both dot blots and western blots, the membranes were then incubated in blocking buffer
for 1 hour and incubated in primary antibodies overnight at 4℃. The membranes were washed
three times with wash buffer and then incubated in secondary antibodies at room temperature
for 1 hour. The membranes were rewashed and rinsed twice with distilled water. After blotting
water off, the membranes were covered in detection reagent. Protein detection was carried out




Table 3: List of Antibody Dilutions Used for Flow Cytometry Analysis
Antibody Conjugation Dilution Source
Rat Anti-Mouse CD14 Allophycocyanin 1: 50 BD Pharminogen[560634]
Normal Rat IgG Allophycocyanin 1: 50 Santa Cruz
Biotechnology[sc-516646]
These dilutions were recommended in the data sheet from the manufacturers.
Using trypan blue exclusion method, 105 macrophages were counted and resuspended in 50`l
staining buffer, and 1`l of target antibody was added to the macrophages. The mixture was vor-
texed lightly and incubated in the dark on ice for 30 minutes. Unbound antibodies were washed
away twice by resuspending cells in PBS, centrifuging at 200xg for 5 minutes and discarding
the supernatant. Finally, the macrophages were resuspended in 300`l of staining buffer and
transferred to FACS analysis tubes [ThermoFisher Scientific, UK]. Fluorescence was detected
using a 0.7micron insert on the BD FACSAria II flow cytometer, and 104 events were acquired.
Data was obtained through the FACSDiva software [BD, UK] and used for further analysis.
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Chapter 9
Data and In Silico Analysis Procedures
1 In Silico Analysis
In Silico analysis of mouse protein sequences obtained from Uniprot database was carried out
using GPS-PAIL 2.0 [221], and R Statistical Programming Software (packages used were: Pep-
tides, Biostrings, phangorn, tidyverse, ape, seqinr, rentrez, msa, and ASEB). Both gene (rentrez
package) and protein sequences were aligned using multiple sequence alignment (msa package).
The physicochemical properties of peptides were analysed using Peptides package. Phylogenetic
trees were made using maximum parsimony with SeaView version 4 [222] and phangorn package.
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Table 4: Sequence IDs
Protein Uniprot ID GenBank ID
CD14 Q4FJP7 NA
CREBBP P45481 NM001025432, NM004380
ELP3 NA NM001253812, NM018091
EP300 B2RWS6 NM177821, NM001429
KAT2A Q9JHD2 NM020004, NM001376227
KAT2B Q9JHD1 NM020005, NM003884
KAT5 NA NM001362372, NM182710
KAT6A NA NM001081149, NM006766
KAT6B NA NM017479, NM012330
KAT8 NA NM026370, NM182958
LPCAT1 Q3TFD2 NM145376, NM024830










Protein sequences were obtained from Uniprot database, and gene sequences were obtained
from GenBank database. NA indicates that the protein or gene sequence for that molecule was
not retrieved and used for analysis.
2 ELISA and RT-qPCR Data Analysis
Microsoft Excel was used to calculate the average and standard error for values of all technical
and biological replicates and independent. The graphs were made using Graphpad Prism 8.0
software. For data analysis of the gene expression of TLR4 and adapter proteins; CC values for
each treatment were normalised to the endogenous control (ATP5B/GAPDH) to get XCC values.
The XCC values were normalised to the negative control (unstimulated samples) to give XXCC
values. These values were used to calculate the relative quantity using the formula (2−XXC ). The
relative quantity of LPS-treated samples was normalised to the relative quantity of the control
siRNA. Finally, to emphasise the down-regulation of gene expression, 1 was subtracted from all
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values, so that the control was = 0.
3 Blot Image Data Analysis
ImageJ/Fiji software was used for the analysis of Western blot and dot blot images. The back-
ground was subtracted, and the densitometry was measured. The average and standard error for
values obtained from densitometry measurement were calculated using Microsoft Excel software,
and the graphs were made in GraphPad Prism 8.0 software.
4 Flow Cytometry Analysis
Flow cytometry data and graphs were analysed and made using FlowJo version 10.6.1 software.
5 Statistical Analysis
GraphPad Prism 8.0 and R statistical programming software were used for statistical analysis
of data. The statistical significance of the difference between the mean values of two treatments
was analysed using Brown-Forsythe and Welch’s ANOVA with Dunnet’s T3 multiple comparison






Characteristics of RAW264.7 Cells
RAW264.7 cell lines are widely used immortalised cell lines derived from monocytes present
in ascites fluid in mice, and transformed by Abelson Murine Leukemia Virus. They are adherent
cell lines that efficiently take up RNA or DNA [37]. This chapter demonstrates the macrophage-
like morphology of RAW264.7 cells and other cell characteristics such as viability, growth curve,
and macromolecular components.
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1 Morphology of RAW264.7 Cells
Figure 8: RAW264.7 Cells in Culture Medium.
The image was captured at 400x magnification using a 40x objective lens. The white arrows
are pointing to elongated cells.
RAW264.7 cells exhibit macrophage features such as phagocytic activities, inflammatory re-
sponse to microbial pathogens, and the release of lysozymes. Active macrophages often present
an elongated appearance, whereas dormant or M2-like macrophages present a circular appear-
ance [223–225]. RAW264.7 cells in figure 8 exhibit both elongated and circular appearance, indi-
cating the presence of both dormant or M2-like and activated or M1-like macrophages.
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2 Viability of RAW264.7 Cells Before and After Transfec-
tion
Figure 9: Cell Viability of RAW264.7 Macrophages in DMEM or OptiMEM Culture
Medium.
At least 90% of Untreated RAW264.7 cells were viable when cultured in DMEM and
OptiMEM. LPS reduced the cell viability significantly to 70 – 80%, whereas, transfection of
RAW264.7 cells with control siRNA reduced the cell viability but this was not statistically
significant.
LPS is known to reduce the viability of RAW264.7 cells [226], as little as 0.5ng/ml LPS inhibits
RAW264.7 cell growth by 50% [37]. Figure 9 shows a similar result, with 100ng/ml LPS sig-
nificantly reducing the cell viability. On the other hand, cells transfected with control siRNA
showed reduced viability; however, this was not significant. RNA interference is an invasive
procedure; hence, it reduces cell viability [227], and OptiMEM has reduced serum which slows
down cell growth and may contribute to reduced cell viability [228]. Nonetheless, a previously
optimised concentration of siRNA and transfection reagent was used for our studies, thereby
reducing the level of cell death during RNA interference [175].
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3 Growth Curve of RAW264.7 Cells
Figure 10: Growth Curve of RAW264.7 Cells.
y= Number of Cells (G106), x = Hours. Doubling time in hours. The curve fit used in
5-Parameter logistic fit from nplr package in R statistical programming software. Weighted
goodness of fit = 0.999.
A>FCℎ'0C4 = (8=0;<>D=C − =8C80;<>D=C)/=8C80;<>D=C
>D1;8=6)8<4 = 3DA0C8>=((!=2)/(!=(1 + A>FCℎ'0C4))
The phases of growth curves include the lag phase, the logarithmic phase, the plateau phase,
and the decline phase. The lag phase shows the time RAW264.7 cells takes to adjust to the
culture medium and environmental conditions. The logarithmic phase is the most viable phase
of cell growth, where the cells proliferate exponentially. The cells stop proliferating at the plateau
phase, and start dying during the decline phase [229].
The lag phase is about 30 hours long, the logarithmic phase is between 30 hours to 80 hours,
and the plateau phase is between 80 hours to 120 hours. The doubling time can vary in different
culture conditions. Previous research [229] showed that the doubling time for RAW264.7 cells
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was 12 hours. Moreover, the logarithmic phase begins just after the doubling time in figure 10;
likewise, the logarithmic phase for RAW264.7 cells began at approximately 12 hours [229].
4 Protein and Total RNA Quantities in RAW264.7 Cells
Table 5: Total RNA and Protein Quantitation Data
Treatment Total RNA (ng/`l) Protein(`g/ml)
No siRNA 1678.83±179.74 1491.641±787.09
Control siRNA 1896.33±322.2 1752.227±112.35
LPCAT2 siRNA 2284±614.53 1506.857±858.65
Control siRNA + LPS 1936±363.54 2077.69±1461.37
LPCAT2 siRNA + LPS 1840.83±157.65 2234.96±1631.25
This data is an average of at least 3 independent experiments. Total RNA was isolated and
counted using Nanodrop 2000. Protein was not purified but was measured from whole cell











































































































Macromolecules in cells include proteins, nucleic acids, and polysaccharides. They make up 26%
of total cell weight, whereas water makes up 70% of total cell weight [230]. The macromolecular
composition of cells can vary depending on the complexity and size of the cell. For instance, bac-
terial cells have lower quantities of macromolecules compared with mammalian cells [31]. Figure
11 shows that the total RNA in RAW264.7 cells is within 20pg to 40pg, whereas, total protein
is within 5`g to 10`g. A typical mammalian cell consists of 10 to 30pg total RNA, and mRNA
makes up to 5% of total RNA. Furthermore, the protein quantity should be higher than the
mRNA quantity [207,231]. Table 5 shows the typical protein and RNA concentration with no
account for cell number.
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Chapter 11
Validation of Antibodies, Gene Silencing,
and RT-qPCR
siRNA mediates gene silencing by targeting mRNA for degradation [215]; therefore, mRNA
levels were analysed after gene silencing procedure to confirm the knockdown efficiency. More-
over, endogenous controls were GAPDH and ATP5B for sample-to-sample variations [232]. For
validation of antibodies, synthesised proteins determined the specificity of the antibodies. Where
necessary, isotype controls were also used to determine antibody specificity. This chapter shows
the results that validate the efficiency of the procedures used.
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1 Cycle Threshold Values of Endogenous Controls
Figure 12: Threshold Cycle Values (Ct) for GAPDH and ATP5B.
GAPDH Ct values fall within 15.5 to 16.5, with 1 outlier at 17.95 and 2 outliers at
approximately 13. On the other hand, ATP5B Ct values fall within 17.22 to 17.94.
After several experimental studies, ATP synthase (ATP5f1) was chosen as the best housekeeping
gene and GAPDH as the third-best from 12 candidate housekeeping genes. The expression of
GAPDH and ATP5f1 was stable for up to ten days. In our study, no experiment involving cell
culture lasted more than 10 days [219]. Therefore, GAPDH and ATP5B should be stable and
good housekeeping genes for RT-qPCR.
A previous paper [219] showed that GAPDH had cycle threshold values between 16 to 17,
whereas, ATP synthase (ATP5f1) had cycle threshold values between 18 to 20. Although the
values in figure 12 are slightly lower, it is worth noting that similar to the publication, ATP5B
has higher Ct values than GAPDH, and ATP5B is more stable than GAPDH.
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2 Confirmation of Gene Silencing
In figure 13, the highest fold reduction of RNF19B mRNA was after 24 hours. Therefore,
RNF19B silencing was carried out for 24 hours for all experiments. Similarly, in [233,234], knock-
out of RNF19B in immune cells was carried out for 24 hours. The optimal time for knockdown
of LPCAT2 in RAW264.7 cells was determined as 48 hours [175]. Therefore, the same conditions
and procedure was used here. Figure 13C shows that the fold mRNA expression of LPCAT2











































































































































































































3 Validation of Antibodies Used For Immunoassays
Figure 14: Validation of RNF19B Antibody using RNF19B Blocking Peptide.
The antibody was blocked with synthesised RNF19B blocking peptide from Aviva Biosciences.
The blots of blocked and unblocked RNF19B antibodies were compared. RNF19B band was
found between 80kDa and 100kDa.
Figure 15: Validation of AcetylLysine Antibody.
After immunoprecipitation of TLR4, 20ng of artificially acetylated bovine serum albumin was
added to the samples prepared for western blot. IP: Immunoprecipitation; WB: Western Blot.
80
Figure 16 shows the sensitivity of IL6, TNFU, and IP10 antibodies. IP10 antibody was the most
sensitive because it could detect ≤ 100pg/ml of IP10, whereas, IL6 and TNFU antibodies could
detect ≥ 100pg/ml.
Figure 14 shows the specific band for RNF19B. The band at 100kDa shows in blot labelled
unblocked, but not in blot labelled blocked. RNF19B is a novel protein, recently discovered [235];
therefore, a more specific antibody for RNF19B may be developed in the future as more studies
on RNF19B is being carried out.
Figures 15 and 17 show that, as expected, the isotype controls do not detect the target pro-
tein. Figure17B shows a blot of TLR4 after immunoprecipitation of acetylated proteins using
acetyllysine antibody. Figure 15 confirms that this antibody detects acetyllysine proteins because





























































































































































































































































































































































































Optimal Concentrations and Durations For
Analysing Gene and Protein Expression
mRNA and protein levels in cells depend on several factors underlying the various stages
during synthesis. Despite this, it is more common to estimate protein levels by measuring the
mRNA amount. The mRNA levels of a high number of molecules are often increased after
stimulation from 4 hours, and protein levels at approximately 24 hours [236–238]. This chapter
shows the best times to analyse protein and mRNA levels of molecules studied. It also shows
the best concentration of ligands to use.
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1 Optimal Response Times for mRNA and Protein Expres-
sion of IL6, IP10, IFNV, TNFU.
Research has shown different kinetics of LPS-induced TNFU responses from macrophages. TNFU 
had the highest response at 8 hours after stimulation of RAW264.7 cells with 10ng/ml LPS [73]. 
Moreover, alveolar macrophages produced the highest response of TNFU at 6 hours and declined 
slightly at 24 hours, after stimulation with 1000ng/ml of LPS [239]. However, similar to Figure 
19, human lung macrophages stimulated with 1`g/ml LPS produced the highest expression of 
TNFU after 24 hours. The variance in time of peak response may be due to various experimental 
conditions. PolyIC- and FSL1-stimulated macrophages showed similar TNFU kinetics (Figures 
18 and 19) [240].
In Figure 18 and Figure 19, RAW264.7 macrophages showed the highest responses of IL6 protein 
at 24 hours. Likewise, IL6 peaked at 24 hours when macrophages were stimulated with heat-
killed bacteria [241]. Spleen cells showed similar IL6 kinetics when stimulated with LPS and 
FSL-1 [96]. Finally, in bronchial epithelial cells, PolyIC stimulated the highest response of IL6 at 24 
hours [242]. Monocytes stimulated with vesicular stomatitis virus and LPS produced the highest 
response of IP10 at 24 hours, in the same manner, shown in figures 18 and 19 [243]. The results in 
figures 18 and 19 are consistent with published work [73,240,244,245].
100ng/ml of LPS was used throughout this project as it is the same concentration used for 
preceding projects. As mentioned in the abstract, this project is a build-up from previous 
experiments that used the same cell model (RAW264.7) and culture conditions [161,175].
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Figure 18: Optimal Response Time for IL6, TNFU, IP10, and IFNV mRNA Expres-
sion.
RAW264.7 cells were stimulated with either 100ng/ml Smooth LPS, 1ng/ml FSL1, or 100`g/ml
PolyIC in 96-well plates for 0-24 hours. Each bar and error bar represents Mean ± Standard
Error of Mean. TNFU peaked at 6 hours when induced by FSL1 and PolyIC, however, with
LPS it peaks at 3 hours. IP10 peaks at 3 hours when induced by LPS, however, FSL1- and
PolyIC-induced IP10 shows a similar fold expression at both 3 hours and 6 hours. IL6 mRNA
expression peaked at 6 hours with LPS and PolyIC stimulation, however, FSL1 induced the
highest expression of IL6 at 24 hours. At 6 hours, FSL1- and PolyIC-induced IFNV mRNA




































































































































































































































































































































































2 Optimal Duration for Surface Expression of CD14
Figure 20: Time-Response Curves of CD14 Surface Expression.
A – Gating of RAW264.7 Macrophages to Separate Cells from Debris. For FACS analysis on
RAW264.7 macrophages, polygon gates separated debris from cells. 75.2 is the percentage of
the cell population that fall into the polygon gate. Only cells in the polygon gates were
examined. FSC-A – Area of Forward Scatter; SSC-A – Area of Side Scatter. B – Surface
Expression Kinetics of CD14 After E. coli O111: B4 LPS Stimulation of RAW264.7 Cells.
RAW264.7 cells were stimulated with 100ng/ml LPS for 0-24 hours in 6-well plates. Cell
surface expression was analysed by Flow Cytometry using APC tagged CD14 antibody. Y-axis
shows the frequency of cells; X-axis shows the area (A) of APC fluorescence. APC-A-
represents the percentage of the cell population that do not have APC fluorescence. APC-A+
represents the percentage of the cell population that have APC fluorescence. The line graph on
the bottom right corner shows the fold change of APC fluorescence relative to 0 hours. CD14
surface expression was down-regulated from 4 - 16 hours, but at 24 hours, the surface
expression of CD14 upregulated to just above the basal level. N=3; Each data point represents
the fold change in the percentage of cells with CD14-APC fluorescence.
The selected side scatter for monocyte populations was between 50K to 250K in a previous pub-
lication [246]. Any observation with side scatter and forward scatter less than 50K was excluded
as debris. This supports the result shown in figure 20A. Furthermore, LPS down-regulates the
surface expression of CD14; however, after 24 hours, the surface expression of CD14 is upreg-
ulated (Figure 20B). Previous research has shown supporting evidence that CD14 is initially
down-regulated after LPS challenge and increases after 24 hours [247–249].
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3 Optimal Duration for Expression of RNF19B
Kinetics of LPS-induced RNF19B protein expression showed the highest expression at 16 hours
when RAW264.7 cells stimulated with 400ng/ml LPS [250], supporting the result shown in figure
21B. On the other hand, LPS significantly induced RNF19B gene expression at both 2 hours
and 16 hours (figure 21A). The results suggest that there is a secondary induction of RNF19B
at 16 hours. In natural killer cells, the kinetics of IL2-induced RNF19B mRNA increased up to
12 hours. Therefore, it could be that the secondary induction of RNF19B gene expression is a

















































































































































































































































































Regulation of TLRs 2-, 3-, and 4-Mediated
Expression of Pro-Inflammatory Molecules
By LPCAT2
Having established that the time of optimal mRNA and protein expression in RAW264.7 cells,
further experiments were carried out to analyse the effect of LPCAT2 silencing. This chapter
presents the outcome of LPCAT2 silencing on mRNA and protein levels of CD14, TLR4, MD2,
IFNV, TNFU, IP10, and IL6 after stimulating RAW264.7 cells with LPS, FSL1, and PolyIC.
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1 Smooth LPS-Induced Expression and Secretion
Figure 22: LPCAT2 Silencing Reduces Smooth LPS-induced IL6, TNFU, IP10, and
IFNV mRNA Expression.
RAW264.7 cells were stimulated with 100ng/ml smooth LPS in 12-well plates for 6 hours.
Smooth LPS induced ≥8000 fold of IL6, however, LPCAT2 silencing reduced the expression to
≤2000 fold. Smooth LPS induced 15-fold of TNFU mRNA expression, but LPCAT2 silencing
reduced it to ≤10 fold. Smooth LPS induced more than 250-fold of IP10, but LPCAT2
silencing reduced the expression to ≤200 fold. Smooth LPS induced 12-fold of IFNV mRNA
expression, but LPCAT2 silencing reduced the expression to 5-fold. Each bar and error bar







































































































































































































LPCAT2 silencing significantly reduced the expression of IL6, TNFU, IFNV, and IP10 in RAW264.7
cells after stimulation with LPS (figures 22 and 23). It has been shown previously that inhibition
of LPCAT reduced the expression of TNFU and IL6 protein after stimulation of cells with LPS
or Pam3CysK by preventing translocation of TLR4 to the lipid raft [198,251]. Moreover, over-
expression of LPCAT2 increases the expression of TNFU and IL6, while reducing the expression
of pro-resolving cytokines [175]. However, in these studies, neither IFNV nor IP10 was studied.
Our results show that like TNFU and IL6, LPCAT2 silencing suppresses LPS induction of IFNV
and IP10.
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2 Rough LPS-Induced Expression and Secretion
Figure 24: Effect of LPCAT2 Silencing on Rc and Re LPS-induced IL6, TNFU, IP10,
and IFNV mRNA Expression.
Rc and Re LPS induced; IL6 mRNA expression to ≥4000 fold, 40 fold of TNFU mRNA
expression, ≥600 fold of IP10 mRNA expression, ≥21 fold of IFNV mRNA expression.
LPCAT2 silencing had no significant effect on the mRNA expression of all cytokines presented
here. Each bar and error bar represents Mean ± Standard Error of Mean.
Smooth and rough chemotypes may differ in their mechanism of inducing inflammation. For
instance, rough LPS from B. abortus strains of bacteria are more potent in inducing the release





























































































































































































so, rough chemotype of E. coli LPS is more potent than the rough chemotype of B. abortus
LPS [93]. Furthermore, similar to figures 24 and 25, smooth LPS and rough LPS were differ-
entially influenced by pulmonary surfactant protein in a published research [252]. The effect
of pulmonary surfactant protein A on Rc LPS-induced TNFU was similar to O111:B4, how-
ever, Re LPS-induced TNFU was significantly different. This differential effect was attributed
to CD14-dependency. Rough LPS is less CD14-dependent compared to smooth LPS because
CD14-deficiency selectively prevents the sensing of smooth LPS but not rough LPS [89,253].
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3 FSL1- and PolyIC-Induced Expression and Secretion
Figure 26: Effect of LPCAT2 Silencing on FSL1- and PolyIC-induced IL6, TNFU,
IP10, and IFNV mRNA Expression.
FSL-1 induced 100 fold of IL6 mRNA expression and PolyIC induced ≥10000 fold. FSL1
induced only 5-fold of IP10 mRNA expression and PolyIC induced ≥400 fold. FSL1 and
PolyIC induced ≥15 fold of TNFU mRNA expression. FSL1 and PolyIC induced ≥5000 fold of
IFNV mRNA expression. LPCAT2 silencing only caused a significant fold reductionin
PolyIC-induced IL6 and IP10 mRNA expression. Each bar and error bar represents Mean ±
Standard Error of Mean.
Our results show that LPCAT2 silencing did not have any significant influence on FSL1-induced


























































































































































































































CAT inhibitors reduced the secretion of TNFU and IL6 from cells stimulated by Pam3CysK (a
TLR2/1 ligand). No studies have shown the effect of LPCAT inhibition or LPCAT2 silencing on
macrophage inflammatory responses stimulated by FSL1 (a TLR2/6 ligand). However, FSL1 is
also known to be a putative TLR2/10 ligand [254,255]. TLR10 exists in mouse macrophages as a
pseudogene, and it is a pro-resolving receptor [256–259]. Therefore, a possible explanation for the
absence of a significant effect of LPCAT2 silencing could be that FSL1 is also stimulating the
TLR2/10 receptor which, may cancel out any effects LPCAT2 silencing is having on TLR2/6
receptor. Moreover, since the normal function of TLR2/10 receptor is pro-resolving, it is possible
that LPCAT2 silencing may cause a reverse effect, thereby creating an equilibrium for TNFU
transcriptional synthesis.
LPCAT2 silencing reduced both PolyIC-induced mRNA and protein expression of IL6 and
IP10. On the other hand, LPCAT2 silencing does not influence the mRNA expression of PolyIC-
induced TNFU and IFNV (figures 26 and 27). In macrophages, double-stranded RNA is capable
of activating both NF^B pathway and IRF pathway. It binds to TLR3, RIG-I/MDA5, and
PKR to activate these pathways [109,113,260]. Silencing of RIG-I reduced TNFU and IL6 expres-
sion [261]. However, RIG-I and MDA-5 are cytosolic receptors for double-stranded RNA. In our
experiments, PolyIC was not transfected into the cells; therefore, our results show the effects
of interaction between the surface receptor for double-stranded viral RNA, TLR3, and PolyIC.
The expression and enzymatic activity of LPCAT2 were induced by LPS, but not by PolyIC,
suggesting that LPCAT2 may not be involved in PolyIC-induced inflammation [186]. Contrarily,
figures 26 and 27 suggest that LPCAT2 regulates PolyIC-induced IL6 and IP10. The reason for
this is unclear. It is possible that LPCAT2 silencing is influencing an unknown pathway; further
research will confirm this.
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4 Regulation of CD14, TLR4, and MD2 Expression By LP-
CAT2
Figure 28: LPCAT2 Silencing Significantly Reduces LPS-induced Expression of Total
CD14 Protein.
Smooth LPS E. coli O111: B4 significantly induced CD14 protein expression, however,
LPCAT2 silencing also significantly reduced CD14 protein expression. * - p≥0.05. Each bar
and error bar represents Mean ± Standard Error of Mean. – indicates the absence of
treatment; + indicates the presence of treatment.
Figure 20 shows that CD14 expression increases at 24 hours; therefore, the effect of LPCAT2
silencing on CD14 protein expression at 24 hours was analyzed. In figures 28 and 29, LPCAT2
silencing caused a significant reduction of smooth LPS-induced CD14 protein and mRNA ex-
pression. Previous work has shown that CD14 and TLR4 mRNA is over-expressed in RAW264.7
cells over-expressing LPCAT2 [175]. There is no published work that shows the effect of LPCAT2
silencing or over-expression on MD2. Consistent with figure 24, figure 30 shows that LPCAT2














































































































































































































































































































































































































































Regulation of RNF19B Localisation and
Expression By LPCAT2
LPCAT2 silencing suppresses LPS-induced acylation of RNF19B [203]. This finding raised
some research questions that led to studying the regulation of RNF19B expression by LPCAT2
during inflammation in RAW264.7 cells. RNF19B was first identified in the 1990’s [235], and it
was named Natural Killer Lytic-Associated Molecule (NKLAM). Moreover, they found selective
expression of RNF19B by activated macrophages, cytotoxic T-lymphocytes, and natural killer
cells. RNF19B exists in 2 isoforms as a result of alternative splicing; a 731 residues isoform
and a 587 residues isoform [262]. It is an E3 ubiquitin ligase, and a homolog of Dorfin also
called RNF19A. URKL1 co-localises with RNF19B, and is used as a substrate for ubiquitin E3
ligase activity [263]. RNF19B was found in cytoplasmic granules in natural killer cells [235], in
the endoplasmic reticulum in epithelial cancer cells [264], and phagosomes in macrophages [250].
RNF19B knockout mice have shown reduced inflammation in natural killer cells [250]. Moreover,
macrophages derived from RNF19B knockout mice were deficient in killing bacteria. Recently,
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RNF19B has been shown to regulate inflammation in macrophages by; controlling the expression
of inducible Nitric Oxide Synthase; regulating NF^B phosphorylation and its translocation to
the nucleus, and regulating STAT phosphorylation and hence regulation of inflammation of
STAT1 [233,265]. This chapter shows the effect of LPCAT2 silencing on RNF19B expression and
function.
1 Subcellular Localisation of RNF19B
Figure 31: LPS Increases the Expression of RNF19B In Lipid Raft Domain of
RAW264.7 Macrophages.
GAPDH was used as a marker for cytosolic fractions and Cholera Toxin was used as a marker
for membrane fractions. Western blot analysis of the sub-cellular fractions showed the
expression of RNF19B in the lipid raft. Cholera toxin has a higher expression in lipid raft
domains. N=3.
The subcellular localisation of a protein is critical for its function. LPCAT2 localises in the endo-
plasmic reticulum, lipid rafts, and lipid droplets which play significant roles in lipid metabolism
and signalling [188]. Nonetheless, Lipid rafts are known sites for LPS-induced TLR4 signalling
occur [149]. GM1 gangliosides are abundant in lipid rafts [149], and cholera toxin recognises and
binds to GM1 gangliosides [266], hence, it was used as a marker for the membrane fractions. As
105
seen in figure 31, the expression of Cholera toxin is higher in the lipid raft than in the non-
raft fraction. There is no difference in the expression of RNF19B in the lipid raft after LPS
stimulation, however, its presence in the non-raft membrane fraction increased.
2 mRNA and Protein Expression of RNF19B
LPS stimulation induced the gene expression of RNF19B. However, LPCAT2 silencing did not
have any significant effect on the induction of RNF19B gene expression (Figure 32). Western
blot analysis revealed that LPS-induced protein expression of RNF19B significantly reduced af-
ter LPCAT2 silencing (figure 33). This result suggests that LPCAT2 silencing does not influence
the transcriptional regulation of RNF19B but might be causing degradation of RNF19B. There
is no previous research that shows that LPCAT2 silencing influences RNF19B expression. How-
ever, since previous work from our lab has shown that LPCAT2 silencing reduces LPS-induced
RNF19B acylation [203], it could be that acylation of RNF19B prevents its degradation. Acyla-
tion is known to stabilise proteins [209]. Therefore, LPCAT2 silencing would promote RNF19B
















































































































































































































































































































































3 Regulation of IL6, TNFU, IP10, and IFNV Expression
and Secretion By RNF19B
Figure 34: IFNV mRNA Expression
All ligands significantly induced IFNV. RNF19B silencing significantly increased LPS-induced
IFNV mRNA, but had no significant effect on FSL1 and PolyIC-induced IFNV mRNA
expression.
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Figure 35: IL6, TNFU, IP10 mRNA Expression and Secretion
Left – mRNA Expression. Right – Protein Expression. FSL1 did not induce a significant
amount of IP10, but significantly induced TNFU and IL6. PolyIC and LPS induced significant
amounts of IP10, IL6, and TNFU. RNF19B silencing only caused reduced expression of LPS-
and PolyIC-induced IL6 and IP10. Each bar and error bar represents Mean ± Standard Error
of Mean.
The expression of STAT1, along with MCP1 and IFNW in RNF19B-silenced macrophages, is
significantly reduced [233]. However, the expression of IL6, IP10, TNFU, and IFNV in RNF19B-
knockdown macrophages is not known. NF^B activation also reduced in macrophages from
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RNF19B knockout mice [250]. Production of IL6, IP10, and TNFU are dependent on NF^B ac-
tivation. Therefore, there is an expectation that the abundance of these cytokines will reduce
in RNF19B-silenced-macrophages. Even so, figures 34 and 35 shows that RNF19B does not
only induce cytokines dependent on NF^B activation but also reduces IRF3 or IRF7 activa-
tion. TRIF-dependent induction of IFNV by LPS and PolyIC reduced with RNF19B silenced.
PolyIC induces RNF19B expression [234]. Hence, RNF19B may be involved in PolyIC-induced
inflammation. RNF144B, a protein in the same family as RNF19B, was shown to be a negative
regulator of PolyIC-induced inflammation in fish cells [267]. Moreover, RNF19A, a homolog of
RNF19B regulates TLR signalling induced by Pam3CSK4 (TLR2 ligand) and PolyIC in THP-
1 macrophage-like cells [268]. These reports show supporting evidence that other E3 ubiquitin
ligases like RNF19B regulate inflammation in macrophages.
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Chapter 15
LPCAT2 Influences Lysine Acetylation
Some acyl modifications that are commonly known to regulate LPS-induced inflammation
include; S-palmitoylation, lysine-acetylation, and N-myristoylation [269]. S-palmitoylation refers
to the addition of palmitate [a 16-carbon fatty acid] to cysteine residues on proteins. Over 5000
proteins in the human proteome are S-palmitoylated [269]. It is an enzymatically reversible modi-
fication that functions mainly to direct proteins to lipid raft microdomains and other membrane
subdomains [269–272]. N-myristoylation is the addition of the 14-carbon fatty acid [Myristate]
to N-terminal glycine residues of proteins. Only about 150 proteins were N-myristoylated in
the human proteome [269]. Therefore, N-myristoylation is not as common as S-palmitoylation.
However, it is also essential for regulating protein association and dissociation from cell mem-
branes [269,271,272]. Lysine-acetylation is the addition of acetyl groups from acetyl-CoA to lysine
residues on proteins. It is known to regulate gene expression, and protein stability by regu-
lating crosstalk with the Ubiquitin-Proteasome pathway, this eventually influences the folding
or function of the protein. Lysine-acetylation was initially recognised in histones; however,
over 1700 proteins are now known to undergo lysine acetylation [273–275]. There is evidence of
post-translational acylation of some proteins that are important for LPS-induced inflammation.
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These include;
• Lysine acetylation of IRFs 3 and 7
• TRAM myristoylation which regulates its association with TRIF to mediate TLR sig-
nalling [276].
• Lysine acetylation of MyD88, which causes its degradation [277]
• S-Palmitoylation of MyD88 [278]
• S-palmitoylation of TLR2, which regulates its surface expression [208]
• Lysine acetylation of RelA, which prolongs its transcriptional activity by preventing ubiq-
uitylation and proteasomal degradation of the protein [279].
In Silico Prediction of binding sites of modification, have been commonly used to predict
protein modifications or protein-protein interactions. These are carried out by computer pro-
grams designed to recognise established modification sites or binding sites from protein se-
quences [32–34,221,280]. Here, computational software predicts lysine acetylation of proteins in-
volved in TLR signalling and the properties of the predicted lysine-acetylated peptides (Tables
6-8).
This chapter presents results that suggest that LPCAT2 regulates lysine acetylation.
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1 In Silico Prediction of Lysine Acetylation
Table 6: In Silico Prediction of Lysine Acetylation of TLR4 Signalling Proteins Using
GPS-PAIL Version 2.0.
Protein Position Peptide Score Cutoff Acetyltransferase
CD14 NA NA NA NA NA
Mal 23 PASSTPSKKPRDKIA 0.74 0.66 EP300
Mal 23 PASSTPSKKPRDKIA 2 1.9 KAT2A
Mal 23 PASSTPSKKPRDKIA 2.27 1.69 KAT2B
Mal 24 PASSTPSKKPRDKIA 2.25 1.69 KAT2B
MD2 NA NA NA NA NA
MyD88 NA NA NA NA NA
TLR4 817 KNALLDGKASNPEQ 2.09 1.79 CREBBP
TRAF3 5 ***MESSKKMDAAG 1.28 0.66 EP300
TRAF3 6 ***MESSKKMDAAG 1.20 0.66 EP300
TRAF3 5 ***MESSKKMDAAG 2.95 1.69 KAT2B
TRAF6 NA NA NA NA NA
TRAM 220 ERQQSIWKETRSVS 2.21 1.79 CREBBP
TRAM 5 ***MGVGKSKLDKC 0.94 0.66 EP300
TRAM 5 ***MGVGKSKLDKC 18.2 14.86 HAT1
TRAM 7 ***MGVGKSKLDKC 1.83 1.69 KAT2B
TRAM 10 VGKSKLDKCPLSW 2.68 1.69 KAT2B
TRAM 63 EQDQPEAKGAGPEE 2.04 1.69 KAT2B
TRIF 534 ANTFKTQKLQAQR 2.11 1.79 KAT2B
RelA 310 KRTYETFKSIMKKS 2.32 1.79 CREBBP
RelA 122 NLGIQCVKKRDLEQ 2.08 1.69 KAT2B
NA indicates that no sites of lysine acetylation was detected. Position indicates the position of
the lysine with predicted acetylation. The acetyltransferases that acetylate the lysines were
also predicted based on known information about binding sites of these enzymes. The score
indicates the probability of acetylation. The higher the score, the higher the chance of
acetylation. The cutoff is the number under the threshold. This analysis was carried out using
a high threshold.
Table 7: In Silico Prediction of Lysine Acetylation of TLR4 Using ASEB
Protein Position Peptide Acetyltransferase
TLR4 152 PIGQLITLKKLNVAHNF KAT2A, KAT2B
TLR4 367 NKGSISFKKVALPSLSY CREBBP
TLR4 503 NLTFLDLSKCQLEQISW CREBBP
TLR4 817 KNALLDGKASNPEQ CREBBP
ASEB predicted more peptides to undergo lysine acetylation in TLR4. However, the peptides
selected and shown in this table all have a p-value of p≤0.1.
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Table 8: Properties of Lysine Acetylated Peptides Predicted By In Silico Analysis







Mal PASSTPSKKPRDKIA 15 -1.3 39.3 2.99 Globular
TLR4 PIGQLITLKKLNVAHNF 17 0.29 137.7 2.09 Globular
TLR4 NKGSISFKKVALPSLSY 17 -0.05 91.8 2.99 Globular
TLR4 NLTFLDLSKCQLEQISW 17 0.02 114.7 -1.06 Globular
TLR4 KNALLDGKASNPEQ 15 -1.17 65.3 -0.0004 Globular
TRAF3 ***MESSKKMDAAG 12 -0.84 16.67 -0.0004 Globular
TRAM ERQQSIWKETRSVS 15 -1.71 45.3 1.001 Globular
TRAM ***MGVGKSKLDKC 14 -0.21 76.44 1.94 Globular
TRAM VGKSKLDKCPLSW 15 -0.83 71.33 3.03 Globular
TRAM EQDQPEAKGAGPEE 15 -2.15 13.33 -3.99 Globular
TRIF ANTFKTQKLQAQR 15 -1.19 58.67 3.99 Globular
A high hydrophobicity index indicates a lipophilic or membranous protein. The aliphatic index
show the thermostability of the peptide. Four peptides show a negative charge because they
contain more acidic amino acids. As expected all peptides are predicted to be globular because
of their low hydrophobicity index.
Figure 36: Analysis of Relatedness of LPCAT2 Gene and Other Lysine Acetyltrans-
ferases of Human and Mouse Species
A – Relatedness of genes from human species. B – Relatedness of genes from mouse species.
The length of the lines indicate the degree of relatedness. A short line indicates a closer
relation. The human genes are more closely related than the mouse genes.
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Figure 37: Analysis of Relatedness of LPCAT2 Protein Sequence and Other Lysine
Acetyltransferases of Mouse specie.
The percentage of gaps after sequence alignments was analysed. LPCAT2vsLPCAT1 had the
least gaps as expected. LPCAT2 had 40% of gaps in its alignments with KAT2A and KAT2B,
however, there was 80% of gaps in the alignments with CREBBP and EP300.
2 Analysis of Pan Lysine Acetylation
Since LPCAT2 silencing did not show a significant effect on TLR4, which is the primary signalling
mediator in response to LPS, post-translational acylation of the proteins was considered as a
mechanism of LPCAT2 influencing TLR4 function. First, the effect of LPCAT2 silencing on
acetylation of proteins in the presence or absence of LPS was analysed. RNA interference
silenced LPCAT2 in RAW264.7 macrophages, and the macrophages lysed for analysis. A pan-
acetylated-lysine antibody detected protein lysine acetylation – the fold expression normalised to
acetylated alpha-tubulin expression, and negative controls (unstimulated samples). Stimulation
of the macrophages with LPS caused an increase in proteins around 10kDa and some proteins
between 100kDa and 50kDa. However, some proteins between 50kDa and 10kDa reduced. This
data suggests that LPS is regulating inflammation by influencing lysine acetylation of proteins.
116
Moreover, LPCAT2 silencing caused a decrease in the expression of acetylated proteins around
100kDa and 10kDa but caused an increase in others. Many of the acetylated proteins that
reduced in LPS-stimulated macrophages did not change with LPCAT2 silenced. However, two
bands of acetylated proteins were increased after LPCAT2 silencing (Figure 38). These results
show that LPCAT2 is influencing the lysine acetylation of proteins; however, it is unclear if
LPCAT2 silencing influences the changes in protein lysine acetylation induced by LPS.
Figure 38: LPCAT2 Silencing Reduces the Expression of Proteins with Acetyl-Lysine
Modification.
RAW264.7 cells were stimulated with 100ng/ml E. coli O111: B4 LPS for 0.5 hours in T25
flasks. Western Blot analysis of cell lysates measured the expression of proteins with acetylated
lysine modification. Densitometry using ImageJ software. GraphPad Prism 8.0 was used to
create the Heat Map. The western blot image shows acetylated lysine proteins before and after
LPCAT2 silencing; the peaks show the optical density of the bands in the western blot image,
and the heat map shows the fold change of acetylated protein expression normalised to
acetylated alpha-tubulin. LPCAT2 silencing reduced the expression of acetylated proteins at
100kDa and ≤10kDa. N≥3.
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3 Analysis of TLR4 Lysine Acetylation
TLR4 protein molecule has a size of about 95–100kDa. In figure 38, two bands around 100kDa
reduced after the LPCAT2 silencing. Moreover, in silico prediction implies TLR4 is acetylated.
Therefore, to confirm the presence of lysine acetylation on TLR4, it was analysed for the pres-
ence of lysine acetylation. LPCAT2 was silenced in RAW264.7 macrophages for 48 hours and
stimulated with LPS for 30 minutes. Then TLR4 or lysine-acetylated proteins precipitated from
macrophage lysates using either TLR4 antibody or pan-acetylated lysine antibody. Then blots
of TLR4 or acetylated lysine residues were used to confirm lysine acetylation of TLR4. Figure
39A shows lysine acetylation of TLR4, but LPS stimulation had no significant effect on TLR4
acetylation. To further confirm that the acetylation detected was on TLR4, RNA interference
silenced TLR4 for 48 hours in RAW264.7 macrophages. Then lysine-acetylated proteins were
precipitated, and the samples analysed for the presence of TLR4. Figure 39B shows that TLR4
was present in the pool of lysine-acetylated proteins, and it reduced when TLR4 was silenced
(figure 39C).
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Figure 39: Detection of Acetyl-Lysine Modification of TLR4 Protein.
RAW264.7 Macrophages were stimulated with 100ng/ml E. coli O111: B4 LPS for 0.5 hours in
T25 flasks. A – TLR4 was isolated from cell lysates and analysed for acetylated lysine
modification. Reversely, acetylated lysine proteins were isolated and analysed for TLR4. The
western blot images show that TLR4 has acetylated lysine residues. B – To confirm that the
protein detected is TLR4, TLR4 was silenced for 48 hours, then acetylated lysine proteins were
isolated from cell lysates and analysed for TLR4. In correlation with the results in [B], TLR4
silencing reduced the detected acetylated lysine residues of TLR4. C – TLR4 silencing reduced
more than 70% of TLR4 protein expression. IP – immunoprecipitation; WB – western blot
analysis. – indicates the absence of treatment; + indicates the presence of treatment.
Since TLR4 showed lysine acetylation, there was an analysis of the effect of LPCAT2 si-
lencing on lysine acetylation of TLR4. Figure 40 shows that LPCAT2 silencing reduced TLR4
acetylation by over 50% (See figure 17 for full blot) – a dot blot of TLR4 from the same volume
of precipitates was used as a volume control.
119
Figure 40: LPCAT2 Silencing Reduces Acetylation of TLR4
RAW264.7cells were stimulated with 100ng/ml E. coli O111:B4 LPS for 0.5 hours in T25
flasks. TLR4 was isolated from cell lysates and analysed for acetylated lysine modification.
Western blot analysis of the same volumes of TLR4 precipitates (with or without LPCAT2
silencing) detected acetyl-lysine residues. Therefore, dot blots of the same volumes of the
TLR4 precipitates were controls for protein amount. After LPCAT2 silencing, acetylated lysine
residues of TLR4 was reduced by 60%. IP – immunoprecipitation; WB – western blot analysis.
– indicates the absence of treatment; + indicates the presence of treatment.
Lysine-acetylation regulates LPS-induced TLR4 signalling proteins such as HMGB1, IRFs,
and NF^B. However, there is no journal publication showing that TLR4 is acetylated or that its
acetylation regulates its signalling. This study suggests that TLR4 is acetylated (Figure 39) and
that lysine acetylation of TLR4 might be involved in regulating its signalling. S-Palmitoylation of
TLR2 was crucial for its surface expression because it increases the hydrophobicity of TLR2 [208].
Their results showed that inhibition of TLR2 palmitoylation decreased its surface expression.
Therefore, this would inhibit a string of downstream events that would lead to inflammation.
This data is supporting information that shows that post-translational acylation of a toll-like
receptor can regulate its function.
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Moreover, a thesis [281] described lysine acetylation of TLR4 on K732 and K813 in LPS-stimulated
RAW264.7 macrophages. TLR4 co-localised with CREBBP and downregulation of CREBBP
reduced TLR4 acetylation. Mutation of K732 and K813 revealed that prevention of TLR4 acety-
lation suppresses its interaction with MyD88, TRAM and TRIF [281]. Although this study did
not confirm what lysine residues are acetylated, it also shows lysine acetylation of TLR4.
In the same vein, TLR4 co-localizes with LPCAT2 [161]. However, there is no explanation
for the role of LPCAT2 during its co-localisation with TLR4. LPCAT2 silencing influenced
the expression of lysine-acetylated proteins and reduced TLR4 acetylation (Figure 40). This
result is a novel suggestion that LPCAT2 influences protein lysine acetylation; further confir-
matory evidence is required to establish this as a fact. LPCAT2 is only known to acetylate
lysoPAF [193]; however, this research suggests a novel role for LPCAT2 as a lysine acetyltrans-
ferase. Downregulation of LPCAT2 expression suppresses TLR4 lysine acetylation; however, the
specific acetylated lysine residues influenced by LPCAT2 are yet to be determined. It may be
that like CREBBP [281], LPCAT2 is necessary for the interaction of TLR4 with other downstream
signalling proteins. There is also the possibility that LPCAT2 silencing reduces the expression





In order to study the role of LPCAT2 on LPS-induced TLR signalling, the expression
of LPS receptors was studied in LPCAT2-silenced macrophages and compared with regular
macrophages. LPCAT2 expression reduced with its gene expression silenced using short in-
terfering RNAs specifically designed to silence LPCAT2 (figure 13C). Unlike other methods for
suppressing gene expression, RNA interference is a more potent and specific method for studying
protein function [282]. Gene expression of LPCAT2 and RNF19B confirmed the efficiency of gene
silencing (figure 13). Gene expression was measured by real-time quantitative PCR because it
was the best method for this study; it is a more sensitive method for measuring gene expression,
compared with northern blot analysis.
Furthermore, it is suitable for measuring a small scale gene expression, unlike microarray analysis
which is more suitable for large scale studies [283–285]. On the other hand, SDS-PAGE separated
proteins from whole lysates. Then western blot analysis detected these proteins using target
antibodies. Immunoblotting of proteins is a more specific and highly sensitive method for de-
tecting proteins. Other methods, such as protein-tags or mass spectrometry, are more laborious




Inflammatory Responses in RAW264.7
Cells
TLR4 gene expression downregulated by both smooth and rough chemotypes of LPS; how-
ever, LPCAT2 silencing did not attenuate its downregulation. TLR4 gene expression also did
not show any differential responses after LPCAT2 silencing with regards to the chemotype of
LPS. The result is in line with reports that have shown that TLR4 protein and gene expression
downregulated during inflammatory conditions [280,289,290]. On the other hand, CD14 increased
in LPS-stimulated macrophages. In support of this, previous research has shown that LPS tran-
scriptionally upregulates by CD14 [291]. Here we found an approximately 2-fold increase in CD14
protein expression after 24 hours of LPS stimulation.
Similarly, there was an increase in CD14 mRNA and protein expression, only after 48 hours
of LPS stimulation [291]. It is important to note that they used 1ng/ml of LPS, whereas here
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100ng/ml of LPS was used; a lower concentration may cause a delay in the transcriptional reg-
ulation of protein expression. MD2 protein expression was also unchanged after stimulating
cells with LPS [292]. This report is supporting evidence for the results of MD2 gene expression
shown here; LPCAT2 silencing did not have any statistically significant influence on the gene
expression of MD2. However, LPS-induced CD14 expression (both protein and gene) reduced
in macrophages with silenced LPCAT2. LPS did not induce CD14 surface expression; it was
downregulated from 4 - 16 hours and restored to just above basal levels at 24 hours. Previous
research has shown that CD14 surface expression upregulated after 48 hours [249,291]. A reduced
CD14 expression would result in reduced production of CD14-dependent pro-inflammatory cy-
tokines which is pivotal to TLR4 and TLR2 mediated inflammatory response [253,293,294]. This
is further evidence that LPCAT2 regulates LPS-induced TLR4 signalling by influencing CD14
expression.
1 Alteration in GlycosylPhosphatidylInositol Abundance in
Macrophage Membrane May Lead To CD14 Shedding
Membrane phospholipid remodelling (Lands Cycle) described by William Lands [184] is associated
with lipid raft formation [295], endocytosis, and membrane diversity and asymmetry [156]. Glyco-
sylphosphatidylinositol (GPI) can be remodelled to lyso-glycosylphosphatidylinositol (LysoGPI).
GPI serves as an anchor to membrane proteins such as CD14. Cleavage of GPI from CD14 by
phospholipases results in shedding of CD14 into the extracellular space. GPI is covalently at-
tached to CD14 by post-translational modification. Therefore, the anchoring of CD14 to GPI is
highly dependent on the availability of GPI on the membrane [296]. LPCAT2 is a crucial enzyme
in the phospholipid remodelling cycle and is responsible for acylating lysophosphatidylcholine
125
and acetylating lysoPAF. Although it does not catalyse the acylation of lysoGPI, it may in-
duce biochemical processes that lead to increased production of lysoGPI. Like other LPCATs,
LPCAT2 silencing increases the abundance of lysophosphatidylcholine in the macrophage mem-
brane by suppressing its acylation [297]. Therefore, this may cause a shift in the equilibrium
of enzymatic activities in the Lands cycle that would favour phospholipase activity, leading to
increased amounts of lysophospholipids. Lysophosphatidylcholine is known to bind with high
affinity to G2A receptor [298,299]. This receptor increases the activity of phospholipase C. As a
result of increased phospholipase C activity, the rate of GPI cleavage increased. Hence, there is
an increased amount of lysoGPI in the membrane [300,301]. CD14 anchored to lysoGPI cannot be
retained on the membrane. Therefore, enhanced anchoring of CD14 to lysoGPI would promote
shedding of CD14 from the membrane [302]. This phenomenon is a possible explanation for the
differential effect of LPCAT2 on CD14 gene and protein expression.
Figure 41: A Model of Imbalance in the Equilibrium of Lands Cycle Caused by
LPCAT2 Silencing.
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2 Internalisation and The Endocytic Pathway
The internalisation of the LPS receptor complex is dependent on the recognition of LPS by
CD14/TLR4/MD2. Silencing or neutralization of CD14 and TLR4 prevents internalisation of
LPS by macrophages [275,303–305]. There is also experimental evidence of differential response
of macrophage endocytosis to various chemotypes of LPS [253]. Therefore, it was pertinent to
study the influence of LPCAT2 silencing on the expression of LPS receptors [TLR4, CD14,
and MD2] after stimulating RAW264.7 macrophages with smooth and rough chemotypes of
LPS. Smooth LPS is more dependent on CD14 than rough LPS, and CD14 is also essential
for endocytosis of the LPS receptor complex [293]. The results imply that LPCAT2 could be
influencing internalisation of the LPS receptor complex by reducing CD14 expression leading to
the suppression of both MyD88-dependent signallings of TLR2 and TLR4, and TRIF-dependent
signalling of TLR3 and TLR4 [293,306].
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Chapter 17
LPCAT2 Regulates RNF19B Protein
Expression in RAW264.7 Cells
1 Acylation of RNF19B May Regulate Its Location and
Stability
In Silico prediction of S-palmitoylation, N-myristoylation, and lysine acetylation in RNF19B
revealed the presence of possible sites for these lipid modifications. Similarly, a previous study,
which showed that LPCAT2 silencing suppressed acylation of proteins, and mass spectrometry
data revealed RNF19B as a top hit [203].
1.1 Acylation could control RNF19B subcellular location
Fluorescence microscopy is commonly used to identify the subcellular location of a protein. How-
ever, in this study, subcellular fractions were separated by differential centrifugation, which has
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the limitation of contamination between subcellular fractions. Contamination was minimised in
this study by rinsing each fraction thoroughly before centrifuging to obtain the next fraction.
Here, stimulation of macrophages with LPS caused an increased expression of RNF19B in the
non-raft fraction, but not in the lipid raft microdomain. One of the significant functions of acy-
lation is to determine the localisation of acylated proteins to membrane lipid domains [307,308].
Therefore, the increased RNF19B expression in the membrane fraction might be a result of in-
creased acylation of RNF19B after LPS stimulation of RAW264.7 macrophages. Further studies
will be required to confirm the reason for increased expression of RNF19B in the lipid rafts, and
the role of LPCAT2 in lipid raft expression of RNF19B.
1.2 Acylation could regulate RNF19B protein expression by enhancing
its stability
In order to test this hypothesis, there was an analysis of the time-response curves for RNF19B
gene and protein expression. The results show that RNF19B gene has a biphasic induction after
LPS stimulation, and the protein increased at 24 hours. RAW264.7 macrophages stimulated
with 400ng/ml of LPS had high expression of RNF19B protein at 16 hours and 24 hours [250].
This report supports the results shown here. The kinetics of RNF19B gene expression after
LPS stimulation in RAW264.7 macrophages is not published. However, the kinetics of RNF19B
gene expression in natural killer cells stimulated by IFNV or IL2 shows induction at 6 hours
(IFNV) and 12 hours (IL2) [235]. The biphasic induction of RNF19B gene expression in LPS-
stimulated RAW264.7 macrophages is a novel finding. It may be caused by secondary stimula-
tion of RAW264.7 macrophages by LPS-induced Type I Interferon or Interleukin. LPCAT2 did
not affect the gene expression of RNF19B.
On the other hand, the protein expression of RNF19B reduced after LPCAT2 silencing. Further
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research would be necessary to confirm the mechanism of reduction of RNF19B protein expres-
sion after LPCAT2 silencing. There is evidence that acylation protects proteins from being
degraded by preventing ubiquitylation, thereby enhancing protein stability [308]. Therefore, a
possible explanation based on previous results is that reduced RNF19B acylation caused by the
LPCAT2 silencing results in the instability of RNF19B protein by allowing its ubiquitylation;
thereby targeting it for degradation. This result implies that LPCAT2 is not influencing the
transcriptional regulation of RNF19B protein but is enhancing its degradation. In line with
the results in chapter 14, RNF19B plays an essential role in LPS-induced inflammation [265].
In their study, RNF19B silencing resulted in suppressed NF^B activation, which is pivotal to
TLR2 and TLR4 signalling. Therefore, this study implies that LPCAT2 regulates LPS-induced
inflammation by regulating RNF19B protein expression.
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Chapter 18
LPCAT2 Regulates Lysine Acetylation
That May Influence Inflammation
This study postulated that LPCAT2 silencing would affect the expression of TLR4; how-
ever, our data shows that LPCAT2 silencing does not influence TLR4 expression (see chapter
13). Previous research has shown that LPCAT inhibition reduces TLR4 signalling by preventing
translocation of TLR4 to lipid raft microdomains [198]. Various kinds of acylation are responsi-
ble for protein translocation and protein-protein interactions. Palmitoylation of TLR4 did not
show in a recent experiment carried out in our lab [203]; however, acetylation [which is another
catalytic reaction of LPCAT2] could be responsible for regulating TLR4 signalling. Therefore,
there was a test of the hypothesis that LPCAT2 influences lysine acetylation in this project.
First, in silico prediction of acylation in proteins associated with TLRs was carried out using
GPS-PAIL and ASEB. This analysis identified potential sites for palmitoylation and acetylation
catalysed by CREBBP (Table 6 - 8). This result corresponds to published results [281], which
showed that CREBBP acetylated TLR4 in macrophages.
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There are three primary methods for detecting lysine acetylation of proteins; these include;
radiolabelling, immunotechniques, and mass spectrometry [309]. Immunoprecipitation and im-
munoblotting were appropriate for this study because it is less expensive and highly sensitive
as it can detect as little as 1ng of antigens [310]. Several papers have published evidence that
alpha-tubulin is acetylated; therefore, acetylated alpha-tubulin was a positive control for detect-
ing pan-acetylated proteins [311–313]. This study shows a novel finding that LPCAT2 silencing
influences lysine acetylation of proteins (Figure 40). However, it is not clear whether the effect
of LPCAT2 silencing is dependent on LPS because LPCAT2 silencing also affected lysine acety-
lation in the absence of LPS stimulation (data not shown). Since it is a pan-lysine-acetylation
study, there is an assumption that LPCAT2 silencing affects LPS-induced lysine acetylation of
some proteins but not all. This assumption is evident for proteins at 100kDa and about 10kDa.
Histones commonly have a size of about 10kDa; therefore, the result suggests that LPS induces
lysine acetylation of histones and implies for the first time that LPCAT2 silencing could be
reducing LPS-induced lysine acetylation of histones. There are implications for the role of His-
tone acetylation in LPS-induced inflammation [314,315]. Hence, this study implies that LPCAT2
silencing regulates LPS-induced inflammation by influencing lysine acetylation of histones.
Furthermore, although the effect of LPS on lysine acetylation of proteins at 100kDa is not very
obvious, there is an apparent reduction in lysine acetylation of 100kDa proteins after LPCAT2
silencing. Many proteins have a size of nearly 100kDa; however, HSP90 and TLRs are the known
inflammatory proteins of about that size. Mass spectrometric analysis of the 90 - 100kDa bands
will be required to identify the proteins and also to identify all the other proteins whose bands
are not distinguishable. There is no published evidence of lysine acetylation of TLR4; how-
ever, speculations based on a PhD thesis [281] and the results from in silico prediction indicate
that TLR4 could be one of the proteins shown at 100kDa in figure 38. Therefore, there was
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a postulation that TLR4 is acetylated and LPCAT2 regulates its acetylation. Either TLR4 or
lysine-acetylated proteins were isolated to test this hypothesis. Blots of acetyl-lysine proteins
and TLR4 shows the presence of lysine acetylation in TLR4; however, LPS did not increase or
decrease the expression of lysine-acetylated proteins (Figure 39A). In order to confirm that the
bands detected are indeed TLR4, TLR4 siRNA silenced TLR4 in RAW264.7 macrophages, and
a pool of lysine-acetylated proteins precipitated. The blot for TLR4 from precipitated proteins
shows an apparent reduction of acetylated TLR4 when TLR4 is silenced (Figure 39B). Hav-
ing confirmed that TLR4 is acetylated, the effect of LPCAT2 silencing on lysine acetylation of
TLR4 was studied. The result shows for the first time that LPCAT2 silencing reduces lysine
acetylation of TLR4 (Figure 40). Here, the results collectively show that regulation of protein




Limitations and Scope for Further
Research
1 Limitations
Several limitations, such as time constraints, limited funds, and the model used, have affected
this project.
• Due to limited funds and time-constraints, further research on lysine acetylation of TLR4
and localisation of RNF19B could not be carried out. The scope for further research in
these areas is discussed below.
• The cell model used for this project is a secondary cell line, more time and funds would
have allowed further research on primary cell lines and in vivo models to determine if the
research can be translated for clinical relevance.
134
2 Scope for Further Research
• Based on the results shown in chapter 15, it will be worth unfolding the identity of the
acetylated proteins that are affected by LPCAT2 silencing. This experiment will involve
treating RAW264.7 macrophages with LPS after silencing LPCAT2. The macrophages
will then be collected and prepared for immunoprecipitation of acetylated proteins. SDS-
PAGE analysis will separate the acetylated proteins in each sample. Gel staining will reveal
bands affected by LPCAT2 silencing; these bands will then be excised and prepared for
mass spectrometric analysis [316]. Identifying the acetylated proteins regulated by LPCAT2
will give more insight into its mechanism of action. Macrophage functions are dependent on
the phospholipid composition of its membrane. Therefore, it will be essential to know how
LPCAT2 changes the phospholipid composition of the macrophage membrane and hence,
its function. This experiment will involve a similar method (described above); however,
lipids will be separated and identified instead of proteins.
• This study shows results that suggest TLR4 acetylation by LPCAT2; however, confirma-
tion of what sites of TLR4 are acetylated requires further studies. Moreover, the role of
TLR4 acetylation in inflammation is unclear and needs to be studied. Due to the similarity
in the structure and function of TLRs, it will also be interesting to see if LPCAT2 modifies
them post-translationally or influences their expression in macrophages.
• From chapter 14, we suggest that RNF19B localises in the lipid raft and LPCAT2 regulates
its acylation. However, there is still a considerable gap in knowledge about the acylation
of RNF19B. The primary step for confirmatory evidence would be to detect the site of
acylation in RNF19B. Then, the mutation of the site of acylation will allow further studies
on the role of acylation on RNF19B function. Enhanced microscopic studies would also
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• LPCAT2 regulates LPS-induced CD14 protein expression.
• LPCAT2 regulates protein lysine acetylation.
• LPCAT2 regulates pro-inflammatory cytokine secretion induced by TLR2 and TLR3.
• LPCAT2 regulates inflammation by influencing the protein expression of RNF19B.
2 Novel Results
• LPCAT2 silencing causes a reduction of CD14 protein and gene expression.
• LPCAT2 silencing reduces PolyIC-induced IL6 gene and protein expression.
• LPCAT2 silencing reduces RNF19B protein expression, but not its gene expression.
• RNF19B found in lipid raft fraction of RAW264.7 macrophages.
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• RNF19B silencing reduces PolyIC-induced IL6 and IP10 expression .
• LPCAT2 silencing influences lysine acetylation of proteins.
• TLR4 shows the presence of acetylated lysine residues.
• LPCAT2 silencing reduces the acetylation of lysine residues in TLR4.
In conclusion, this study shows further evidence that LPCAT2 regulates inflammation in
macrophages. We also suggest new mechanisms by which LPCAT2 regulates inflammation, these
include; regulation of CD14 expression, regulation of RNF19B expression, and lysine acetylation
of proteins, especially TLR4.
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